User login
Spontaneous Resorption of a Large Cervical Herniated Nucleus Pulposus
C7 Pars Fracture Subadjacent to C7 Pedicle Screw Instrumentation at the Caudal End of a Posterior Cervical Instrumentation Construct
Spontaneous Septic Arthritis of the Lumbar Facet Caused by Methicillin-Resistant Staphylococcus aureus in an Otherwise Healthy Adolescent
Aspiration of a Dental Tool During a Crown Placement Procedure
There are many reports in the medical and dental literature of complications arising from a routine delivery of dental care. One complication can include physical injury from swallowing or aspirating foreign objects.1 However, a review of such literature presents a scarcity of documented instances and no long-term evaluation of the aforementioned events.2,3
This report presents the case of a patient who aspirated a hex driver tool during a procedure to place a crown on a dental implant. The aspirated object was subsequently removed through flexible fiberoptic bronchoscopy without complications.
Case Report
An 83-year-old man was referred to the Pulmonary and Critical Care Department of the VA Caribbean Healthcare System in San Juan, Puerto Rico, after a hex driver tool was lost during a procedure to place a crown on a dental implant, performed under topical anesthesia. It was first thought that the patient swallowed the hex driver, since he never experienced or complained of coughing or shortness of breath. A chest radiograph revealed a metal object lying within the right main stem bronchus, for which the patient was referred to the Pulmonary and Critical Care Department (Figure 1).
The patient’s past medical history was remarkable for hypertension and hypercholesterolemia. Outpatient medications included hydrochlorothiazide, simvastatin, aspirin, felodipine, and lorazepam. He had no previous history of dysphagia or neurologic disease. A physical examination revealed expiratory and inspiratory wheezing localized to the right lower lobe without associated rhonchi or crackles. No distress, shortness of breath, or coughing was noted.
A flexible fiberoptic bronchoscopy was performed under conscious sedation with 3 mg of IV midazolam and topical anesthesia with nebulized 4% lidocaine. No mucosal edema, hyperemia, or structural damage was noted during direct visualization of both the right and left bronchopulmonary segments. A metallic object was visualized at the entrance of the right lower lobe. The foreign object had irregular borders, providing multiple edges that made it suitable to be embraced (Figure 2).
Using a radial jaw single-use biopsy forceps 1.8 mm, the physician clinched and retrieved the object through the bronchoscope. The object was retrieved on the same day of the dental procedure almost 5 hours after it was aspirated. The patient tolerated the procedure well; no coughing, oxygen desaturation, or bleeding occurred during the procedure.
After a few hours of observation, a postprocedural radiograph confirmed the removal of the foreign body without evidence of pneumothorax. The patient was discharged, and 24 hours after the incident remained asymptomatic without chest pain, cough, hemoptysis, sputum production, or fever.
Discussion
Foreign-body aspiration and inadvertent swallowing remains underrecognized by clinicians. In the U.S., more than 2,700 people, including more than 300 children, die of foreign-body aspiration each year.4,5 Aspiration or ingestion of a foreign body during a dental procedure is serious and potentially fatal.6 Some of the consequences of an aspirated object are complete or partial airway obstruction, respiratory distress and failure, pneumothorax, and hemorrhage.7 In addition, inadvertent aspiration of foreign objects in asymptomatic patients may not be evident for months, resulting in late complications as postobstructive pneumonia, bronchiectasis, or lung abscess.8 Early recognition and diagnosis of these events are crucial to prevent complications.
Accidental aspiration of foreign objects during dental procedures is not as common as is swallowing. In the normal population, the foreign object enters the gastrointestinal tract in about 92.5% of the time, and the tracheobronchial tree in 7.5% of these instances.
A 10-year review done at the School of Dentistry of the University of North Carolina reported 36 incidents of lost instruments during dental procedures. In only 1 case, an object was aspirated, 25 of the 36 cases were secondary to ingestion, and in the remaining 10 incidents, swallowing or aspiration was ruled out by radiography or after the object’s removal from the patient’s mouth.2 Previous reviews about foreign-body aspiration in adults have reported dental appliances as the second most commonly aspirated foreign objects.4 Of all aspirated objects, the most common site of impaction is the right lower lobe; however, aspiration has been reported in all pulmonary lobes.6
Available literature recognizes that impaction of aspirated objects occurred in 56% of instances within the right lower lobe and 33% in the left lower lobe.7,9 Identification of risk factors for aspiration is important for any patient who will undergo dental procedures, such as advanced age (ie, elderly patients may have a decreased gag reflex); neurologic conditions, such as stroke; dementia and other degenerative diseases; the use of topical anesthesia; and altered states of consciousness associated with the use of IV sedation.1,2
The key sign that most dentists recognize when patients aspirate an object during a dental procedure is coughing. It has been reported that coughing resulting from aspiration of foreign objects may range from mild to severe. In this case, the patient was completely asymptomatic during the procedure. The only clue of possible object aspiration was the reported tool loss by the dentist. It is important to always examine, account for, and review all equipment used during dental procedures. Assessment for any lost objects or missing parts of instruments should be done promptly with a high degree of suspicion for possible swallowing or aspiration if an object is missing.
It has been recommended to use a gauze throat screen and rubber dam and to avoid a supine position during a procedure, among other techniques, to minimize risk of ingestion or aspiration.2 Imaging studies should be used for further evaluation of the patient; however, some instruments, such as dental pieces and impression material, may not be identified by plain films. In those cases, further evaluation with more sophisticated imaging techniques, such as computed tomography (CT), should be considered.1-10
In a previous case report of a patient who aspirated a third molar during a dental procedure, a chest film failed to identify it. A chest CT was performed, and the object showed in the right main stem bronchus. In another instance, aspiration of impression material in a 45-year-old man was not observed by chest radiography. In this case, the history of coughing and respiratory symptoms days after the procedure pointed toward aspiration of an object as the culprit, with subsequent identification and removal by flexible fiberoptic bronchoscopy.1-11
Bronchoscopy is the treatment of choice for extraction of aspirated foreign bodies; however, there is still a debate about whether to use flexible or rigid bronchoscopy. The decision is usually made based on the object size, localization, medical facility, and personnel expertise. The rigid bronchoscope has the advantages of offering better control and visualization of the airway and easier use of removal instruments. Its primary disadvantage is that the procedure needs to be done in the operating room under general anesthesia. Flexible fiberoptic bronchoscopy done under conscious sedation and topical anesthesia may be as effective as rigid bronchoscopy and even superior in the case of smaller and more distal impacted objects.10-14
In this case, flexible fiberoptic bronchoscopy was used successfully for the removal of the foreign object. Biopsy forceps were used to grasp the object and retrieve it from the airway without complication.
Conclusion
Aspiration of foreign objects during a dental procedure is a potential life-threatening complication. A high-level of suspicion is needed for early diagnosis and referral of the patient for extraction of the object and further avoidance of complications. Flexible fiberoptic bronchoscopy is a feasible procedure for removal of objects within the airway.
Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.
Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc. , the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.
1. Cameron SM, Whitlock WL, Tabor MS. Foreign body aspiration in dentistry: A review. J Am Dent Assoc. 1996;127(8):1224-1229.
2. Tiwana KK, Morton T, Tiwana PS. Aspiration and ingestion in dental practice: A 10-year institutional review. J Am Dent Assoc. 2004;135(9):1287-1291.
3. Susini G, Pommel L, Camps J. Accidental ingestion and aspiration of root canal instruments and other dental foreign bodies in a French population. Int Endod J. 2007;40(8):585-589.
4. Fields RT Jr, Schow SR. Aspiration and ingestion of foreign bodies in oral and maxillofacial surgery: A review of the literature and report of five cases. J Oral Maxillofac Surg. 1998;56(9):1091-1098.
5. Black RE, Johnson DG, Matlak ME. Bronchoscopic removal of aspirated foreign bodies in children. J Pediatr Surg. 1994;29(5):682-684.
6. Limper AH, Prakash UBS. Tracheobronchial foreign bodies in adults. Ann Intern Med. 1990;112(8):604-609.
7. Bas¸oglu OK, Buduneli N, Cagirici U, Turhan K, Aysan T. Pulmonary aspiration of a two-unit bridge during a deep sleep. J Oral Rehabil. 2005;32(6):461-463.
8. Mahmoud M, Imam S, Patel H, King M. Foreign body aspiration of a dental bridge in the left main stem bronchus. Case Rep Med. 2012;2012:1-4.
9. Jackson C, Jackson CL. Diseases of the Air and Food Passages of Foreign-Body Origin. Philadelphia, PA: Saunders; 1936.
10. Zitzmann NU, Elsasser S, Fried R, Marinello CP. Foreign body ingestion and aspiration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(6):657-660.
11. Elgazzar RF, Abdelhady AI, Sadakah AA. Aspiration of an impacted lower third molar during its surgical removal under local anaesthesia. Int J Oral Maxillofac Surg. 2007;36(4):362-364.
12. Tu CY, Chen HJ, Chen W, Liu YH, Chen CH. A feasible approach for extraction of dental prostheses from the airway by flexible bronchoscopy in concert with wire loops snares. Laryngoscope. 2007;117(7):1280-1282.
13. Ospina JC, Ludemann JP. Aspiration of an extracted molar: Case report. J Can Dent Assoc. 2005;71(8):581-583.
14. Cohen S, Pine H, Drake A. Use of rigid and flexible bronchoscopy among pediatric otolaryngologists. Arch Otoralyngol Head Neck Surg. 2001;127(5):505-509.
There are many reports in the medical and dental literature of complications arising from a routine delivery of dental care. One complication can include physical injury from swallowing or aspirating foreign objects.1 However, a review of such literature presents a scarcity of documented instances and no long-term evaluation of the aforementioned events.2,3
This report presents the case of a patient who aspirated a hex driver tool during a procedure to place a crown on a dental implant. The aspirated object was subsequently removed through flexible fiberoptic bronchoscopy without complications.
Case Report
An 83-year-old man was referred to the Pulmonary and Critical Care Department of the VA Caribbean Healthcare System in San Juan, Puerto Rico, after a hex driver tool was lost during a procedure to place a crown on a dental implant, performed under topical anesthesia. It was first thought that the patient swallowed the hex driver, since he never experienced or complained of coughing or shortness of breath. A chest radiograph revealed a metal object lying within the right main stem bronchus, for which the patient was referred to the Pulmonary and Critical Care Department (Figure 1).
The patient’s past medical history was remarkable for hypertension and hypercholesterolemia. Outpatient medications included hydrochlorothiazide, simvastatin, aspirin, felodipine, and lorazepam. He had no previous history of dysphagia or neurologic disease. A physical examination revealed expiratory and inspiratory wheezing localized to the right lower lobe without associated rhonchi or crackles. No distress, shortness of breath, or coughing was noted.
A flexible fiberoptic bronchoscopy was performed under conscious sedation with 3 mg of IV midazolam and topical anesthesia with nebulized 4% lidocaine. No mucosal edema, hyperemia, or structural damage was noted during direct visualization of both the right and left bronchopulmonary segments. A metallic object was visualized at the entrance of the right lower lobe. The foreign object had irregular borders, providing multiple edges that made it suitable to be embraced (Figure 2).
Using a radial jaw single-use biopsy forceps 1.8 mm, the physician clinched and retrieved the object through the bronchoscope. The object was retrieved on the same day of the dental procedure almost 5 hours after it was aspirated. The patient tolerated the procedure well; no coughing, oxygen desaturation, or bleeding occurred during the procedure.
After a few hours of observation, a postprocedural radiograph confirmed the removal of the foreign body without evidence of pneumothorax. The patient was discharged, and 24 hours after the incident remained asymptomatic without chest pain, cough, hemoptysis, sputum production, or fever.
Discussion
Foreign-body aspiration and inadvertent swallowing remains underrecognized by clinicians. In the U.S., more than 2,700 people, including more than 300 children, die of foreign-body aspiration each year.4,5 Aspiration or ingestion of a foreign body during a dental procedure is serious and potentially fatal.6 Some of the consequences of an aspirated object are complete or partial airway obstruction, respiratory distress and failure, pneumothorax, and hemorrhage.7 In addition, inadvertent aspiration of foreign objects in asymptomatic patients may not be evident for months, resulting in late complications as postobstructive pneumonia, bronchiectasis, or lung abscess.8 Early recognition and diagnosis of these events are crucial to prevent complications.
Accidental aspiration of foreign objects during dental procedures is not as common as is swallowing. In the normal population, the foreign object enters the gastrointestinal tract in about 92.5% of the time, and the tracheobronchial tree in 7.5% of these instances.
A 10-year review done at the School of Dentistry of the University of North Carolina reported 36 incidents of lost instruments during dental procedures. In only 1 case, an object was aspirated, 25 of the 36 cases were secondary to ingestion, and in the remaining 10 incidents, swallowing or aspiration was ruled out by radiography or after the object’s removal from the patient’s mouth.2 Previous reviews about foreign-body aspiration in adults have reported dental appliances as the second most commonly aspirated foreign objects.4 Of all aspirated objects, the most common site of impaction is the right lower lobe; however, aspiration has been reported in all pulmonary lobes.6
Available literature recognizes that impaction of aspirated objects occurred in 56% of instances within the right lower lobe and 33% in the left lower lobe.7,9 Identification of risk factors for aspiration is important for any patient who will undergo dental procedures, such as advanced age (ie, elderly patients may have a decreased gag reflex); neurologic conditions, such as stroke; dementia and other degenerative diseases; the use of topical anesthesia; and altered states of consciousness associated with the use of IV sedation.1,2
The key sign that most dentists recognize when patients aspirate an object during a dental procedure is coughing. It has been reported that coughing resulting from aspiration of foreign objects may range from mild to severe. In this case, the patient was completely asymptomatic during the procedure. The only clue of possible object aspiration was the reported tool loss by the dentist. It is important to always examine, account for, and review all equipment used during dental procedures. Assessment for any lost objects or missing parts of instruments should be done promptly with a high degree of suspicion for possible swallowing or aspiration if an object is missing.
It has been recommended to use a gauze throat screen and rubber dam and to avoid a supine position during a procedure, among other techniques, to minimize risk of ingestion or aspiration.2 Imaging studies should be used for further evaluation of the patient; however, some instruments, such as dental pieces and impression material, may not be identified by plain films. In those cases, further evaluation with more sophisticated imaging techniques, such as computed tomography (CT), should be considered.1-10
In a previous case report of a patient who aspirated a third molar during a dental procedure, a chest film failed to identify it. A chest CT was performed, and the object showed in the right main stem bronchus. In another instance, aspiration of impression material in a 45-year-old man was not observed by chest radiography. In this case, the history of coughing and respiratory symptoms days after the procedure pointed toward aspiration of an object as the culprit, with subsequent identification and removal by flexible fiberoptic bronchoscopy.1-11
Bronchoscopy is the treatment of choice for extraction of aspirated foreign bodies; however, there is still a debate about whether to use flexible or rigid bronchoscopy. The decision is usually made based on the object size, localization, medical facility, and personnel expertise. The rigid bronchoscope has the advantages of offering better control and visualization of the airway and easier use of removal instruments. Its primary disadvantage is that the procedure needs to be done in the operating room under general anesthesia. Flexible fiberoptic bronchoscopy done under conscious sedation and topical anesthesia may be as effective as rigid bronchoscopy and even superior in the case of smaller and more distal impacted objects.10-14
In this case, flexible fiberoptic bronchoscopy was used successfully for the removal of the foreign object. Biopsy forceps were used to grasp the object and retrieve it from the airway without complication.
Conclusion
Aspiration of foreign objects during a dental procedure is a potential life-threatening complication. A high-level of suspicion is needed for early diagnosis and referral of the patient for extraction of the object and further avoidance of complications. Flexible fiberoptic bronchoscopy is a feasible procedure for removal of objects within the airway.
Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.
Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc. , the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.
There are many reports in the medical and dental literature of complications arising from a routine delivery of dental care. One complication can include physical injury from swallowing or aspirating foreign objects.1 However, a review of such literature presents a scarcity of documented instances and no long-term evaluation of the aforementioned events.2,3
This report presents the case of a patient who aspirated a hex driver tool during a procedure to place a crown on a dental implant. The aspirated object was subsequently removed through flexible fiberoptic bronchoscopy without complications.
Case Report
An 83-year-old man was referred to the Pulmonary and Critical Care Department of the VA Caribbean Healthcare System in San Juan, Puerto Rico, after a hex driver tool was lost during a procedure to place a crown on a dental implant, performed under topical anesthesia. It was first thought that the patient swallowed the hex driver, since he never experienced or complained of coughing or shortness of breath. A chest radiograph revealed a metal object lying within the right main stem bronchus, for which the patient was referred to the Pulmonary and Critical Care Department (Figure 1).
The patient’s past medical history was remarkable for hypertension and hypercholesterolemia. Outpatient medications included hydrochlorothiazide, simvastatin, aspirin, felodipine, and lorazepam. He had no previous history of dysphagia or neurologic disease. A physical examination revealed expiratory and inspiratory wheezing localized to the right lower lobe without associated rhonchi or crackles. No distress, shortness of breath, or coughing was noted.
A flexible fiberoptic bronchoscopy was performed under conscious sedation with 3 mg of IV midazolam and topical anesthesia with nebulized 4% lidocaine. No mucosal edema, hyperemia, or structural damage was noted during direct visualization of both the right and left bronchopulmonary segments. A metallic object was visualized at the entrance of the right lower lobe. The foreign object had irregular borders, providing multiple edges that made it suitable to be embraced (Figure 2).
Using a radial jaw single-use biopsy forceps 1.8 mm, the physician clinched and retrieved the object through the bronchoscope. The object was retrieved on the same day of the dental procedure almost 5 hours after it was aspirated. The patient tolerated the procedure well; no coughing, oxygen desaturation, or bleeding occurred during the procedure.
After a few hours of observation, a postprocedural radiograph confirmed the removal of the foreign body without evidence of pneumothorax. The patient was discharged, and 24 hours after the incident remained asymptomatic without chest pain, cough, hemoptysis, sputum production, or fever.
Discussion
Foreign-body aspiration and inadvertent swallowing remains underrecognized by clinicians. In the U.S., more than 2,700 people, including more than 300 children, die of foreign-body aspiration each year.4,5 Aspiration or ingestion of a foreign body during a dental procedure is serious and potentially fatal.6 Some of the consequences of an aspirated object are complete or partial airway obstruction, respiratory distress and failure, pneumothorax, and hemorrhage.7 In addition, inadvertent aspiration of foreign objects in asymptomatic patients may not be evident for months, resulting in late complications as postobstructive pneumonia, bronchiectasis, or lung abscess.8 Early recognition and diagnosis of these events are crucial to prevent complications.
Accidental aspiration of foreign objects during dental procedures is not as common as is swallowing. In the normal population, the foreign object enters the gastrointestinal tract in about 92.5% of the time, and the tracheobronchial tree in 7.5% of these instances.
A 10-year review done at the School of Dentistry of the University of North Carolina reported 36 incidents of lost instruments during dental procedures. In only 1 case, an object was aspirated, 25 of the 36 cases were secondary to ingestion, and in the remaining 10 incidents, swallowing or aspiration was ruled out by radiography or after the object’s removal from the patient’s mouth.2 Previous reviews about foreign-body aspiration in adults have reported dental appliances as the second most commonly aspirated foreign objects.4 Of all aspirated objects, the most common site of impaction is the right lower lobe; however, aspiration has been reported in all pulmonary lobes.6
Available literature recognizes that impaction of aspirated objects occurred in 56% of instances within the right lower lobe and 33% in the left lower lobe.7,9 Identification of risk factors for aspiration is important for any patient who will undergo dental procedures, such as advanced age (ie, elderly patients may have a decreased gag reflex); neurologic conditions, such as stroke; dementia and other degenerative diseases; the use of topical anesthesia; and altered states of consciousness associated with the use of IV sedation.1,2
The key sign that most dentists recognize when patients aspirate an object during a dental procedure is coughing. It has been reported that coughing resulting from aspiration of foreign objects may range from mild to severe. In this case, the patient was completely asymptomatic during the procedure. The only clue of possible object aspiration was the reported tool loss by the dentist. It is important to always examine, account for, and review all equipment used during dental procedures. Assessment for any lost objects or missing parts of instruments should be done promptly with a high degree of suspicion for possible swallowing or aspiration if an object is missing.
It has been recommended to use a gauze throat screen and rubber dam and to avoid a supine position during a procedure, among other techniques, to minimize risk of ingestion or aspiration.2 Imaging studies should be used for further evaluation of the patient; however, some instruments, such as dental pieces and impression material, may not be identified by plain films. In those cases, further evaluation with more sophisticated imaging techniques, such as computed tomography (CT), should be considered.1-10
In a previous case report of a patient who aspirated a third molar during a dental procedure, a chest film failed to identify it. A chest CT was performed, and the object showed in the right main stem bronchus. In another instance, aspiration of impression material in a 45-year-old man was not observed by chest radiography. In this case, the history of coughing and respiratory symptoms days after the procedure pointed toward aspiration of an object as the culprit, with subsequent identification and removal by flexible fiberoptic bronchoscopy.1-11
Bronchoscopy is the treatment of choice for extraction of aspirated foreign bodies; however, there is still a debate about whether to use flexible or rigid bronchoscopy. The decision is usually made based on the object size, localization, medical facility, and personnel expertise. The rigid bronchoscope has the advantages of offering better control and visualization of the airway and easier use of removal instruments. Its primary disadvantage is that the procedure needs to be done in the operating room under general anesthesia. Flexible fiberoptic bronchoscopy done under conscious sedation and topical anesthesia may be as effective as rigid bronchoscopy and even superior in the case of smaller and more distal impacted objects.10-14
In this case, flexible fiberoptic bronchoscopy was used successfully for the removal of the foreign object. Biopsy forceps were used to grasp the object and retrieve it from the airway without complication.
Conclusion
Aspiration of foreign objects during a dental procedure is a potential life-threatening complication. A high-level of suspicion is needed for early diagnosis and referral of the patient for extraction of the object and further avoidance of complications. Flexible fiberoptic bronchoscopy is a feasible procedure for removal of objects within the airway.
Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.
Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc. , the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.
1. Cameron SM, Whitlock WL, Tabor MS. Foreign body aspiration in dentistry: A review. J Am Dent Assoc. 1996;127(8):1224-1229.
2. Tiwana KK, Morton T, Tiwana PS. Aspiration and ingestion in dental practice: A 10-year institutional review. J Am Dent Assoc. 2004;135(9):1287-1291.
3. Susini G, Pommel L, Camps J. Accidental ingestion and aspiration of root canal instruments and other dental foreign bodies in a French population. Int Endod J. 2007;40(8):585-589.
4. Fields RT Jr, Schow SR. Aspiration and ingestion of foreign bodies in oral and maxillofacial surgery: A review of the literature and report of five cases. J Oral Maxillofac Surg. 1998;56(9):1091-1098.
5. Black RE, Johnson DG, Matlak ME. Bronchoscopic removal of aspirated foreign bodies in children. J Pediatr Surg. 1994;29(5):682-684.
6. Limper AH, Prakash UBS. Tracheobronchial foreign bodies in adults. Ann Intern Med. 1990;112(8):604-609.
7. Bas¸oglu OK, Buduneli N, Cagirici U, Turhan K, Aysan T. Pulmonary aspiration of a two-unit bridge during a deep sleep. J Oral Rehabil. 2005;32(6):461-463.
8. Mahmoud M, Imam S, Patel H, King M. Foreign body aspiration of a dental bridge in the left main stem bronchus. Case Rep Med. 2012;2012:1-4.
9. Jackson C, Jackson CL. Diseases of the Air and Food Passages of Foreign-Body Origin. Philadelphia, PA: Saunders; 1936.
10. Zitzmann NU, Elsasser S, Fried R, Marinello CP. Foreign body ingestion and aspiration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(6):657-660.
11. Elgazzar RF, Abdelhady AI, Sadakah AA. Aspiration of an impacted lower third molar during its surgical removal under local anaesthesia. Int J Oral Maxillofac Surg. 2007;36(4):362-364.
12. Tu CY, Chen HJ, Chen W, Liu YH, Chen CH. A feasible approach for extraction of dental prostheses from the airway by flexible bronchoscopy in concert with wire loops snares. Laryngoscope. 2007;117(7):1280-1282.
13. Ospina JC, Ludemann JP. Aspiration of an extracted molar: Case report. J Can Dent Assoc. 2005;71(8):581-583.
14. Cohen S, Pine H, Drake A. Use of rigid and flexible bronchoscopy among pediatric otolaryngologists. Arch Otoralyngol Head Neck Surg. 2001;127(5):505-509.
1. Cameron SM, Whitlock WL, Tabor MS. Foreign body aspiration in dentistry: A review. J Am Dent Assoc. 1996;127(8):1224-1229.
2. Tiwana KK, Morton T, Tiwana PS. Aspiration and ingestion in dental practice: A 10-year institutional review. J Am Dent Assoc. 2004;135(9):1287-1291.
3. Susini G, Pommel L, Camps J. Accidental ingestion and aspiration of root canal instruments and other dental foreign bodies in a French population. Int Endod J. 2007;40(8):585-589.
4. Fields RT Jr, Schow SR. Aspiration and ingestion of foreign bodies in oral and maxillofacial surgery: A review of the literature and report of five cases. J Oral Maxillofac Surg. 1998;56(9):1091-1098.
5. Black RE, Johnson DG, Matlak ME. Bronchoscopic removal of aspirated foreign bodies in children. J Pediatr Surg. 1994;29(5):682-684.
6. Limper AH, Prakash UBS. Tracheobronchial foreign bodies in adults. Ann Intern Med. 1990;112(8):604-609.
7. Bas¸oglu OK, Buduneli N, Cagirici U, Turhan K, Aysan T. Pulmonary aspiration of a two-unit bridge during a deep sleep. J Oral Rehabil. 2005;32(6):461-463.
8. Mahmoud M, Imam S, Patel H, King M. Foreign body aspiration of a dental bridge in the left main stem bronchus. Case Rep Med. 2012;2012:1-4.
9. Jackson C, Jackson CL. Diseases of the Air and Food Passages of Foreign-Body Origin. Philadelphia, PA: Saunders; 1936.
10. Zitzmann NU, Elsasser S, Fried R, Marinello CP. Foreign body ingestion and aspiration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(6):657-660.
11. Elgazzar RF, Abdelhady AI, Sadakah AA. Aspiration of an impacted lower third molar during its surgical removal under local anaesthesia. Int J Oral Maxillofac Surg. 2007;36(4):362-364.
12. Tu CY, Chen HJ, Chen W, Liu YH, Chen CH. A feasible approach for extraction of dental prostheses from the airway by flexible bronchoscopy in concert with wire loops snares. Laryngoscope. 2007;117(7):1280-1282.
13. Ospina JC, Ludemann JP. Aspiration of an extracted molar: Case report. J Can Dent Assoc. 2005;71(8):581-583.
14. Cohen S, Pine H, Drake A. Use of rigid and flexible bronchoscopy among pediatric otolaryngologists. Arch Otoralyngol Head Neck Surg. 2001;127(5):505-509.
Fatigue, arthalgia, amenorrhea—Dx?
THE CASE
A 46-year-old Caucasian female with a history of epilepsy came into our family medicine center complaining of weakness, fatigue, and arthralgia that made it difficult for her to walk. She’d had these symptoms for 6 months and reported having amenorrhea and hot flashes for the past 2 years.
The patient’s blood pressure was 133/72 mm Hg, heart rate was 82 beats per min, and respiratory rate was 20 breaths per min. Her skin was dry without hyperpigmentation, and her sclerae were anicteric. A musculoskeletal examination revealed tenderness of the metacarpophalangeal and metatarsophalangeal joints without edema, deformity, or evidence of synovitis.
She had no history of skin bronzing, jaundice, transfusions, hepatitis, abdominal pain, or diabetes and denied using tobacco, alcohol, or illicit drugs. Her medications included lamotrigine (250 mg BID) and over-the-counter iron supplementation. She had no family history of rheumatoid arthritis, lupus, cirrhosis, hemochromatosis, or other liver disease. Her mother died from colorectal cancer and her father’s cause of death was unknown; her sisters did not have any medical issues. The patient’s lab tests were normal, except for the following: aspartate aminotransferase, 89 U/L (normal, 13-45 U/L); alanine aminotransferase, 80 U/L (normal, 5-57 U/L); and alkaline phosphatase, 132 U/L (normal, 39-117 U/L). Her coagulation panel revealed a prothrombin time of 13.1 seconds, and an international normalized ratio of 1.3. Serology was negative for hepatitis A, B, and C. Additional testing revealed the following: ferritin, 4014.1 ng/dL (normal, 7-282 ng/dL); iron, 210 mg/dL (normal, 40-170 mg/dL); total iron binding capacity, 258 mg/dL (normal, 260-445 mg/dL); and transferrin saturation, 81% (normal, 20%-55%).
Abdominal ultrasonography revealed gallstones, an enlarged spleen, a dilated portal vein, and a fatty liver consistent with cirrhosis. X-rays showed soft-tissue swelling and demineralization in her hands consistent with osteopenia and degenerative arthritis in both feet.
THE DIAGNOSIS
Based on our patient’s complaints of fatigue, weakness, arthralgia, and amenorrhea, as well as her abnormal iron levels, we suspected hereditary hemochromatosis (HH). We ordered HFE genotyping, and the results indicated that the patient was homozygous for the C282Y mutation, confirming our diagnosis.
DISCUSSION
HH is an autosomal recessive disorder of iron homeostasis characterized by increased gastrointestinal iron absorption and tissue deposition of iron. It is caused by mutations in the HFE gene (C282Y or H63D) located on chromosome 6 (locus 6p21) and commonly seen in Northern European Caucasians.1 Approximately 85% of patients with HH are homozygous for C282Y; the H63D mutation can cause HH when in the presence of a single C282Y mutation.1 Men manifest HH symptoms usually between the ages of 40 and 60 years,2 although women may be affected at a later age than men because physiologic blood loss from menstruation and parturition limit the rate at which excess iron is accumulated.2
|
Signs and symptoms of HH include depression, fatigue, restless legs syndrome, weakness, and weight loss.3 In advanced HH, patients may develop progressive skin pigmentation or bronzing, and hypogonadism. Advanced HH can affect the patient’s organs, including the pancreas (diabetes), liver (hepatomegaly, abnormal liver function tests), pituitary gland (amenorrhea, decreased libido, erectile dysfunction), and heart (arrhythmias, congestive heart failure), as well as the musculoskeletal system (joint pain).3,4 The spleen can also be affected after cirrhosis develops. Cirrhosis, hepatocellular carcinoma, and cardiomyopathy can reduce life expectancy.4
Testing for HH
Because symptoms of HH are common and nonspecific, a high degree of clinical suspicion is required for early diagnosis. The differential diagnosis includes conditions related to chronic liver disease or iron overload (TABLE).5 If the diagnosis goes undetected until complications arise, the risk of morbidity and mortality are greatly increased.5
If HH is suspected, serum ferritin concentration and fasting serum transferrin saturation (the ratio of serum iron level to total iron-binding capacity × 100) are recommended as initial tests.5 The normal range of transferrin saturation for males is 15% to 50% and the normal range for females is 12% to 45%. If the transferrin saturation exceeds 50% in women or 60% in men, further evaluation is warranted (FIGURE 1).6,7 The sensitivity and specificity of elevated transferrin saturation for HH are 92% and 93%, respectively.5 These transferrin saturation cutoffs don’t apply to patients with a history of frequent blood transfusion (ie, patients with sickle cell disease or thalassemia).
Additional testing for patients in whom you suspect HH includes:
• a complete blood count, metabolic panel, and coagulation panel
• hepatitis serologies
• imaging (abdominal ultrasound, skeletal radiographs, echocardiogram, abdominal magnetic resonance imaging [MRI])
• a liver biopsy with iron staining and quantitative iron measurements.
The gold standard. Performing a liver biopsy to measure hepatic iron concentration by staining is considered the gold standard test for HH.8 But since genetic testing has become more readily available, liver biopsies aren’t widely used to confirm the diagnosis.8 The diagnosis of HH usually is confirmed by molecular testing for the C282Y and H63D mutations. Liver biopsy may be recommended to document the degree of fibrosis in all homozygotes over age 40 with elevated serum transaminase levels, clinical evidence of liver disease, or a serum ferritin level >1000 mcg/L.7
Phlebotomy helps lower iron levels
Treatment should not be delayed until symptoms develop.3 The mainstay of therapy is phlebotomy.9 If phlebotomy is started before the onset of organ damage, patients can anticipate a normal lifespan.9 Without treatment death may occur from cirrhosis, hepatocellular carcinoma, or cardiomyopathy.
Removal of 1 unit of red blood cells (450-500 mL) results in the loss of approximately 200 mg of iron. Serum ferritin level testing is the most reliable and least expensive method to monitor therapy.9 Iron depletion is complete when the serum ferritin level is 10 to 20 g/L, when the hemoglobin concentration is <11 g/dL, or the hematocrit is <33% for >3 weeks. HH patients need to undergo lifelong phlebotomy to maintain a serum ferritin level <50 g/L. Encourage patients to take in an adequate amount of dietary protein, vitamin B12, and folate to support the accelerated level of erythropoiesis that occurs during therapy.9
Chelation therapy is reserved for patients with advanced disease (eg, those with organ damage) or those who do not respond to phlebotomy.10 Deferoxamine given intravenously (IV) or subcutaneously has been the standard chelation agent. It’s usually administered by continuous subcutaneous infusion using a battery-operated pump at a dose of 40 mg/kg/d for 8 to 12 hours nightly for 5 to 7 nights weekly. A dose of approximately 2 g per 24 hours usually achieves maximal urinary iron excretion.
The use of deferoxamine therapy is limited by cost as well as the need for parenteral therapy, discomfort, inconvenience, and neurotoxicity.5 The US Food and Drug Administration recently approved an oral ironchelating agent, deferasirox, for the treatment of secondary iron overload due to ineffective erythropoiesis. Studies are ongoing to evaluate its potential use in HH.5,9
Our patient’s outcome
Our patient declined liver biopsy and her sisters declined HFE genotyping. Our patient did, however, complete 7 phlebotomies over 4 months. Two months later, she reported shortness of breath during exertion, leg swelling, and palpitations. A chest x-ray revealed a right-sided pleural effusion and an electrocardiogram showed atrial fibrillation with rapid ventricular response. Our patient was admitted for telemetry monitoring and started on diltiazem IV. Echocardiogram showed a restrictive cardiomyopathy, with an ejection fraction of 15% (normal range >55%).
Six weeks later, her ejection fraction decreased to 10%. An MRI of her abdomen showed iron deposition in her liver, pancreas, and lymph nodes (FIGURE 2). She was started on deferoxamine IV and transferred to the coronary care unit for 3 weeks. She was discharged with a diagnosis of class IV heart failure and admitted 2 weeks later for exacerbation of heart failure symptoms. She did not want to pursue a heart transplant. Her condition deteriorated and she expired after a fatal cardiac arrhythmia.
THE TAKEAWAY
Patients with abnormal iron studies and those with evidence of liver disease should be evaluated for HH5 (strength of recommendation [SOR]: A). Fasting serum transferrin saturation and serum ferritin concentration are recommended as initial tests for HH11 (SOR C). Liver biopsy is the gold standard for diagnosis of HH, but the diagnosis usually is confirmed by genetic testing8 (SOR C). Phlebotomy is the mainstay of therapy9 (SOR B). Chelation therapy is reserved for patients with advanced disease or for those who do not respond to phlebotomy10 (SOR C).
Strength of recommendation (SOR)
A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series
1. Matthews AL, Grimes SJ, Wiesner GL, et al. Clinical consult: iron overload--hereditary hemochromatosis. Prim Care. 2004;31:767-770,xii-xiii.
2. Gochee PA, Powell LW. What’s new in hemochromatosis. Curr Opin Hematol. 2001;8:98-104.
3. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256-1262.
4. Adams PC. Hemochromatosis. Clin Liver Dis. 2004;8:735-753,vii.
5. Bacon BR, Adams PC, Kowdley KV, et al; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:328-343.
6. Brandhagen DJ, Fairbanks VF, Baldus W. Recognition and management of hereditary hemochromatosis. Am Fam Physician. 2002;65:853-860.
7. Hash RB. Hereditary hemochromatosis. J Am Board Fam Pract. 2001;14:266-273.
8. Qaseem A, Aronson M, Fitterman N, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;143:517-521.
9. Brissot P, de Bels F. Current approaches to the management of hemochromatosis. Hematology Am Soc Hematol Educ Program. 2006:36-41.
10. US Preventive Services Task Force. Screening for hemochromatosis: recommendation statement. Ann Intern Med. 2006;145:204-208.
11. Borwein S, Ghent CN, Valberg LS. Diagnostic efficacy of screening tests for hereditary hemochromatosis. Can Med Assoc J. 1984;131:895-901.
THE CASE
A 46-year-old Caucasian female with a history of epilepsy came into our family medicine center complaining of weakness, fatigue, and arthralgia that made it difficult for her to walk. She’d had these symptoms for 6 months and reported having amenorrhea and hot flashes for the past 2 years.
The patient’s blood pressure was 133/72 mm Hg, heart rate was 82 beats per min, and respiratory rate was 20 breaths per min. Her skin was dry without hyperpigmentation, and her sclerae were anicteric. A musculoskeletal examination revealed tenderness of the metacarpophalangeal and metatarsophalangeal joints without edema, deformity, or evidence of synovitis.
She had no history of skin bronzing, jaundice, transfusions, hepatitis, abdominal pain, or diabetes and denied using tobacco, alcohol, or illicit drugs. Her medications included lamotrigine (250 mg BID) and over-the-counter iron supplementation. She had no family history of rheumatoid arthritis, lupus, cirrhosis, hemochromatosis, or other liver disease. Her mother died from colorectal cancer and her father’s cause of death was unknown; her sisters did not have any medical issues. The patient’s lab tests were normal, except for the following: aspartate aminotransferase, 89 U/L (normal, 13-45 U/L); alanine aminotransferase, 80 U/L (normal, 5-57 U/L); and alkaline phosphatase, 132 U/L (normal, 39-117 U/L). Her coagulation panel revealed a prothrombin time of 13.1 seconds, and an international normalized ratio of 1.3. Serology was negative for hepatitis A, B, and C. Additional testing revealed the following: ferritin, 4014.1 ng/dL (normal, 7-282 ng/dL); iron, 210 mg/dL (normal, 40-170 mg/dL); total iron binding capacity, 258 mg/dL (normal, 260-445 mg/dL); and transferrin saturation, 81% (normal, 20%-55%).
Abdominal ultrasonography revealed gallstones, an enlarged spleen, a dilated portal vein, and a fatty liver consistent with cirrhosis. X-rays showed soft-tissue swelling and demineralization in her hands consistent with osteopenia and degenerative arthritis in both feet.
THE DIAGNOSIS
Based on our patient’s complaints of fatigue, weakness, arthralgia, and amenorrhea, as well as her abnormal iron levels, we suspected hereditary hemochromatosis (HH). We ordered HFE genotyping, and the results indicated that the patient was homozygous for the C282Y mutation, confirming our diagnosis.
DISCUSSION
HH is an autosomal recessive disorder of iron homeostasis characterized by increased gastrointestinal iron absorption and tissue deposition of iron. It is caused by mutations in the HFE gene (C282Y or H63D) located on chromosome 6 (locus 6p21) and commonly seen in Northern European Caucasians.1 Approximately 85% of patients with HH are homozygous for C282Y; the H63D mutation can cause HH when in the presence of a single C282Y mutation.1 Men manifest HH symptoms usually between the ages of 40 and 60 years,2 although women may be affected at a later age than men because physiologic blood loss from menstruation and parturition limit the rate at which excess iron is accumulated.2
|
Signs and symptoms of HH include depression, fatigue, restless legs syndrome, weakness, and weight loss.3 In advanced HH, patients may develop progressive skin pigmentation or bronzing, and hypogonadism. Advanced HH can affect the patient’s organs, including the pancreas (diabetes), liver (hepatomegaly, abnormal liver function tests), pituitary gland (amenorrhea, decreased libido, erectile dysfunction), and heart (arrhythmias, congestive heart failure), as well as the musculoskeletal system (joint pain).3,4 The spleen can also be affected after cirrhosis develops. Cirrhosis, hepatocellular carcinoma, and cardiomyopathy can reduce life expectancy.4
Testing for HH
Because symptoms of HH are common and nonspecific, a high degree of clinical suspicion is required for early diagnosis. The differential diagnosis includes conditions related to chronic liver disease or iron overload (TABLE).5 If the diagnosis goes undetected until complications arise, the risk of morbidity and mortality are greatly increased.5
If HH is suspected, serum ferritin concentration and fasting serum transferrin saturation (the ratio of serum iron level to total iron-binding capacity × 100) are recommended as initial tests.5 The normal range of transferrin saturation for males is 15% to 50% and the normal range for females is 12% to 45%. If the transferrin saturation exceeds 50% in women or 60% in men, further evaluation is warranted (FIGURE 1).6,7 The sensitivity and specificity of elevated transferrin saturation for HH are 92% and 93%, respectively.5 These transferrin saturation cutoffs don’t apply to patients with a history of frequent blood transfusion (ie, patients with sickle cell disease or thalassemia).
Additional testing for patients in whom you suspect HH includes:
• a complete blood count, metabolic panel, and coagulation panel
• hepatitis serologies
• imaging (abdominal ultrasound, skeletal radiographs, echocardiogram, abdominal magnetic resonance imaging [MRI])
• a liver biopsy with iron staining and quantitative iron measurements.
The gold standard. Performing a liver biopsy to measure hepatic iron concentration by staining is considered the gold standard test for HH.8 But since genetic testing has become more readily available, liver biopsies aren’t widely used to confirm the diagnosis.8 The diagnosis of HH usually is confirmed by molecular testing for the C282Y and H63D mutations. Liver biopsy may be recommended to document the degree of fibrosis in all homozygotes over age 40 with elevated serum transaminase levels, clinical evidence of liver disease, or a serum ferritin level >1000 mcg/L.7
Phlebotomy helps lower iron levels
Treatment should not be delayed until symptoms develop.3 The mainstay of therapy is phlebotomy.9 If phlebotomy is started before the onset of organ damage, patients can anticipate a normal lifespan.9 Without treatment death may occur from cirrhosis, hepatocellular carcinoma, or cardiomyopathy.
Removal of 1 unit of red blood cells (450-500 mL) results in the loss of approximately 200 mg of iron. Serum ferritin level testing is the most reliable and least expensive method to monitor therapy.9 Iron depletion is complete when the serum ferritin level is 10 to 20 g/L, when the hemoglobin concentration is <11 g/dL, or the hematocrit is <33% for >3 weeks. HH patients need to undergo lifelong phlebotomy to maintain a serum ferritin level <50 g/L. Encourage patients to take in an adequate amount of dietary protein, vitamin B12, and folate to support the accelerated level of erythropoiesis that occurs during therapy.9
Chelation therapy is reserved for patients with advanced disease (eg, those with organ damage) or those who do not respond to phlebotomy.10 Deferoxamine given intravenously (IV) or subcutaneously has been the standard chelation agent. It’s usually administered by continuous subcutaneous infusion using a battery-operated pump at a dose of 40 mg/kg/d for 8 to 12 hours nightly for 5 to 7 nights weekly. A dose of approximately 2 g per 24 hours usually achieves maximal urinary iron excretion.
The use of deferoxamine therapy is limited by cost as well as the need for parenteral therapy, discomfort, inconvenience, and neurotoxicity.5 The US Food and Drug Administration recently approved an oral ironchelating agent, deferasirox, for the treatment of secondary iron overload due to ineffective erythropoiesis. Studies are ongoing to evaluate its potential use in HH.5,9
Our patient’s outcome
Our patient declined liver biopsy and her sisters declined HFE genotyping. Our patient did, however, complete 7 phlebotomies over 4 months. Two months later, she reported shortness of breath during exertion, leg swelling, and palpitations. A chest x-ray revealed a right-sided pleural effusion and an electrocardiogram showed atrial fibrillation with rapid ventricular response. Our patient was admitted for telemetry monitoring and started on diltiazem IV. Echocardiogram showed a restrictive cardiomyopathy, with an ejection fraction of 15% (normal range >55%).
Six weeks later, her ejection fraction decreased to 10%. An MRI of her abdomen showed iron deposition in her liver, pancreas, and lymph nodes (FIGURE 2). She was started on deferoxamine IV and transferred to the coronary care unit for 3 weeks. She was discharged with a diagnosis of class IV heart failure and admitted 2 weeks later for exacerbation of heart failure symptoms. She did not want to pursue a heart transplant. Her condition deteriorated and she expired after a fatal cardiac arrhythmia.
THE TAKEAWAY
Patients with abnormal iron studies and those with evidence of liver disease should be evaluated for HH5 (strength of recommendation [SOR]: A). Fasting serum transferrin saturation and serum ferritin concentration are recommended as initial tests for HH11 (SOR C). Liver biopsy is the gold standard for diagnosis of HH, but the diagnosis usually is confirmed by genetic testing8 (SOR C). Phlebotomy is the mainstay of therapy9 (SOR B). Chelation therapy is reserved for patients with advanced disease or for those who do not respond to phlebotomy10 (SOR C).
Strength of recommendation (SOR)
A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series
THE CASE
A 46-year-old Caucasian female with a history of epilepsy came into our family medicine center complaining of weakness, fatigue, and arthralgia that made it difficult for her to walk. She’d had these symptoms for 6 months and reported having amenorrhea and hot flashes for the past 2 years.
The patient’s blood pressure was 133/72 mm Hg, heart rate was 82 beats per min, and respiratory rate was 20 breaths per min. Her skin was dry without hyperpigmentation, and her sclerae were anicteric. A musculoskeletal examination revealed tenderness of the metacarpophalangeal and metatarsophalangeal joints without edema, deformity, or evidence of synovitis.
She had no history of skin bronzing, jaundice, transfusions, hepatitis, abdominal pain, or diabetes and denied using tobacco, alcohol, or illicit drugs. Her medications included lamotrigine (250 mg BID) and over-the-counter iron supplementation. She had no family history of rheumatoid arthritis, lupus, cirrhosis, hemochromatosis, or other liver disease. Her mother died from colorectal cancer and her father’s cause of death was unknown; her sisters did not have any medical issues. The patient’s lab tests were normal, except for the following: aspartate aminotransferase, 89 U/L (normal, 13-45 U/L); alanine aminotransferase, 80 U/L (normal, 5-57 U/L); and alkaline phosphatase, 132 U/L (normal, 39-117 U/L). Her coagulation panel revealed a prothrombin time of 13.1 seconds, and an international normalized ratio of 1.3. Serology was negative for hepatitis A, B, and C. Additional testing revealed the following: ferritin, 4014.1 ng/dL (normal, 7-282 ng/dL); iron, 210 mg/dL (normal, 40-170 mg/dL); total iron binding capacity, 258 mg/dL (normal, 260-445 mg/dL); and transferrin saturation, 81% (normal, 20%-55%).
Abdominal ultrasonography revealed gallstones, an enlarged spleen, a dilated portal vein, and a fatty liver consistent with cirrhosis. X-rays showed soft-tissue swelling and demineralization in her hands consistent with osteopenia and degenerative arthritis in both feet.
THE DIAGNOSIS
Based on our patient’s complaints of fatigue, weakness, arthralgia, and amenorrhea, as well as her abnormal iron levels, we suspected hereditary hemochromatosis (HH). We ordered HFE genotyping, and the results indicated that the patient was homozygous for the C282Y mutation, confirming our diagnosis.
DISCUSSION
HH is an autosomal recessive disorder of iron homeostasis characterized by increased gastrointestinal iron absorption and tissue deposition of iron. It is caused by mutations in the HFE gene (C282Y or H63D) located on chromosome 6 (locus 6p21) and commonly seen in Northern European Caucasians.1 Approximately 85% of patients with HH are homozygous for C282Y; the H63D mutation can cause HH when in the presence of a single C282Y mutation.1 Men manifest HH symptoms usually between the ages of 40 and 60 years,2 although women may be affected at a later age than men because physiologic blood loss from menstruation and parturition limit the rate at which excess iron is accumulated.2
|
Signs and symptoms of HH include depression, fatigue, restless legs syndrome, weakness, and weight loss.3 In advanced HH, patients may develop progressive skin pigmentation or bronzing, and hypogonadism. Advanced HH can affect the patient’s organs, including the pancreas (diabetes), liver (hepatomegaly, abnormal liver function tests), pituitary gland (amenorrhea, decreased libido, erectile dysfunction), and heart (arrhythmias, congestive heart failure), as well as the musculoskeletal system (joint pain).3,4 The spleen can also be affected after cirrhosis develops. Cirrhosis, hepatocellular carcinoma, and cardiomyopathy can reduce life expectancy.4
Testing for HH
Because symptoms of HH are common and nonspecific, a high degree of clinical suspicion is required for early diagnosis. The differential diagnosis includes conditions related to chronic liver disease or iron overload (TABLE).5 If the diagnosis goes undetected until complications arise, the risk of morbidity and mortality are greatly increased.5
If HH is suspected, serum ferritin concentration and fasting serum transferrin saturation (the ratio of serum iron level to total iron-binding capacity × 100) are recommended as initial tests.5 The normal range of transferrin saturation for males is 15% to 50% and the normal range for females is 12% to 45%. If the transferrin saturation exceeds 50% in women or 60% in men, further evaluation is warranted (FIGURE 1).6,7 The sensitivity and specificity of elevated transferrin saturation for HH are 92% and 93%, respectively.5 These transferrin saturation cutoffs don’t apply to patients with a history of frequent blood transfusion (ie, patients with sickle cell disease or thalassemia).
Additional testing for patients in whom you suspect HH includes:
• a complete blood count, metabolic panel, and coagulation panel
• hepatitis serologies
• imaging (abdominal ultrasound, skeletal radiographs, echocardiogram, abdominal magnetic resonance imaging [MRI])
• a liver biopsy with iron staining and quantitative iron measurements.
The gold standard. Performing a liver biopsy to measure hepatic iron concentration by staining is considered the gold standard test for HH.8 But since genetic testing has become more readily available, liver biopsies aren’t widely used to confirm the diagnosis.8 The diagnosis of HH usually is confirmed by molecular testing for the C282Y and H63D mutations. Liver biopsy may be recommended to document the degree of fibrosis in all homozygotes over age 40 with elevated serum transaminase levels, clinical evidence of liver disease, or a serum ferritin level >1000 mcg/L.7
Phlebotomy helps lower iron levels
Treatment should not be delayed until symptoms develop.3 The mainstay of therapy is phlebotomy.9 If phlebotomy is started before the onset of organ damage, patients can anticipate a normal lifespan.9 Without treatment death may occur from cirrhosis, hepatocellular carcinoma, or cardiomyopathy.
Removal of 1 unit of red blood cells (450-500 mL) results in the loss of approximately 200 mg of iron. Serum ferritin level testing is the most reliable and least expensive method to monitor therapy.9 Iron depletion is complete when the serum ferritin level is 10 to 20 g/L, when the hemoglobin concentration is <11 g/dL, or the hematocrit is <33% for >3 weeks. HH patients need to undergo lifelong phlebotomy to maintain a serum ferritin level <50 g/L. Encourage patients to take in an adequate amount of dietary protein, vitamin B12, and folate to support the accelerated level of erythropoiesis that occurs during therapy.9
Chelation therapy is reserved for patients with advanced disease (eg, those with organ damage) or those who do not respond to phlebotomy.10 Deferoxamine given intravenously (IV) or subcutaneously has been the standard chelation agent. It’s usually administered by continuous subcutaneous infusion using a battery-operated pump at a dose of 40 mg/kg/d for 8 to 12 hours nightly for 5 to 7 nights weekly. A dose of approximately 2 g per 24 hours usually achieves maximal urinary iron excretion.
The use of deferoxamine therapy is limited by cost as well as the need for parenteral therapy, discomfort, inconvenience, and neurotoxicity.5 The US Food and Drug Administration recently approved an oral ironchelating agent, deferasirox, for the treatment of secondary iron overload due to ineffective erythropoiesis. Studies are ongoing to evaluate its potential use in HH.5,9
Our patient’s outcome
Our patient declined liver biopsy and her sisters declined HFE genotyping. Our patient did, however, complete 7 phlebotomies over 4 months. Two months later, she reported shortness of breath during exertion, leg swelling, and palpitations. A chest x-ray revealed a right-sided pleural effusion and an electrocardiogram showed atrial fibrillation with rapid ventricular response. Our patient was admitted for telemetry monitoring and started on diltiazem IV. Echocardiogram showed a restrictive cardiomyopathy, with an ejection fraction of 15% (normal range >55%).
Six weeks later, her ejection fraction decreased to 10%. An MRI of her abdomen showed iron deposition in her liver, pancreas, and lymph nodes (FIGURE 2). She was started on deferoxamine IV and transferred to the coronary care unit for 3 weeks. She was discharged with a diagnosis of class IV heart failure and admitted 2 weeks later for exacerbation of heart failure symptoms. She did not want to pursue a heart transplant. Her condition deteriorated and she expired after a fatal cardiac arrhythmia.
THE TAKEAWAY
Patients with abnormal iron studies and those with evidence of liver disease should be evaluated for HH5 (strength of recommendation [SOR]: A). Fasting serum transferrin saturation and serum ferritin concentration are recommended as initial tests for HH11 (SOR C). Liver biopsy is the gold standard for diagnosis of HH, but the diagnosis usually is confirmed by genetic testing8 (SOR C). Phlebotomy is the mainstay of therapy9 (SOR B). Chelation therapy is reserved for patients with advanced disease or for those who do not respond to phlebotomy10 (SOR C).
Strength of recommendation (SOR)
A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series
1. Matthews AL, Grimes SJ, Wiesner GL, et al. Clinical consult: iron overload--hereditary hemochromatosis. Prim Care. 2004;31:767-770,xii-xiii.
2. Gochee PA, Powell LW. What’s new in hemochromatosis. Curr Opin Hematol. 2001;8:98-104.
3. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256-1262.
4. Adams PC. Hemochromatosis. Clin Liver Dis. 2004;8:735-753,vii.
5. Bacon BR, Adams PC, Kowdley KV, et al; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:328-343.
6. Brandhagen DJ, Fairbanks VF, Baldus W. Recognition and management of hereditary hemochromatosis. Am Fam Physician. 2002;65:853-860.
7. Hash RB. Hereditary hemochromatosis. J Am Board Fam Pract. 2001;14:266-273.
8. Qaseem A, Aronson M, Fitterman N, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;143:517-521.
9. Brissot P, de Bels F. Current approaches to the management of hemochromatosis. Hematology Am Soc Hematol Educ Program. 2006:36-41.
10. US Preventive Services Task Force. Screening for hemochromatosis: recommendation statement. Ann Intern Med. 2006;145:204-208.
11. Borwein S, Ghent CN, Valberg LS. Diagnostic efficacy of screening tests for hereditary hemochromatosis. Can Med Assoc J. 1984;131:895-901.
1. Matthews AL, Grimes SJ, Wiesner GL, et al. Clinical consult: iron overload--hereditary hemochromatosis. Prim Care. 2004;31:767-770,xii-xiii.
2. Gochee PA, Powell LW. What’s new in hemochromatosis. Curr Opin Hematol. 2001;8:98-104.
3. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256-1262.
4. Adams PC. Hemochromatosis. Clin Liver Dis. 2004;8:735-753,vii.
5. Bacon BR, Adams PC, Kowdley KV, et al; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:328-343.
6. Brandhagen DJ, Fairbanks VF, Baldus W. Recognition and management of hereditary hemochromatosis. Am Fam Physician. 2002;65:853-860.
7. Hash RB. Hereditary hemochromatosis. J Am Board Fam Pract. 2001;14:266-273.
8. Qaseem A, Aronson M, Fitterman N, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;143:517-521.
9. Brissot P, de Bels F. Current approaches to the management of hemochromatosis. Hematology Am Soc Hematol Educ Program. 2006:36-41.
10. US Preventive Services Task Force. Screening for hemochromatosis: recommendation statement. Ann Intern Med. 2006;145:204-208.
11. Borwein S, Ghent CN, Valberg LS. Diagnostic efficacy of screening tests for hereditary hemochromatosis. Can Med Assoc J. 1984;131:895-901.
Case Studies in Toxicology: Death and Taxus
Case
A 50-year-old man ingests two handfuls of small, red berries that he picked from a shrub in front of his apartment building, with the belief that they would have medicinal value. Two hours later, he developed abdominal cramping and vomited multiple times, followed shortly thereafter by profuse diaphoresis, lethargy, and ataxia. His concerned family brought him to the ED where his vital signs on presentation were: blood pressure (BP), 78/43 mm Hg; heart rate (HR), 50 beats/minute; respiratory rate (RR), 12 breaths/minute; temperature (T), 97.8°F. With the exception of bradycardia, the patient’s cardiac, pulmonary, and abdominal examinations were normal. His skin was diaphoretic, and he had no focal motor or sensory deficits or tremor. Initial laboratory values were: hemoglobin, 12.6 g/dL; sodium, 137 mEq/L; potassium, 4.6 mEq/L; bicarbonate, 20 mEq/L; blood urea nitrogen, 17 mg/dL; creatinine, 2.2 mg/dL; glucose, 288 mg/dL. The patient’s troponin I level was slightly elevated at 0.06 ng/mL; electrocardiogram (ECG) results are shown in Figure 1.
Why do plant poisonings occur?
There is the general belief that what is natural is not only healthful but also safe. This is clearly not true: cyanide, uranium, and king cobras are all natural but hardly safe. While most plants chosen for their purported medicinal properties are generally harmless in most patients when taken in low doses, there are plants that are sufficiently poisonous to be consequential with even relatively small exposures. Some people, often unknowingly vulnerable due to genetic or other causes, are uniquely susceptible to even minute doses.
Humans probably learned about plant toxicity early on—most likely the hard way. To this day, however, the Internet is replete with traditional and avant-garde natural healing remedies involving the use of naturally-derived plant products. These numerous bioactive compounds are often sold in plant form or as extracts, the latter being more concerning given their more concentrated formulation.
Plant misidentification is a common cause of poisoning, whether the intended use is for food or medicine. For example, some mistake “deadly nightshade” (Atropa belladonna) berries, which are deep blue, for blueberries, or pokeweed roots for horseradish roots due to their similar appearances.1
Alternatively, even when a plant is correctly identified, patients may experience adverse effects if they exceed the “therapeutic dose” (eg, dysrhythmia from aconite roots used in traditional Chinese medicine) or if the plant is improperly prepared (eg, hypoglycemia from consuming unripe ackee fruit).2 In addition, a toxic plant such as Jimson weed (Datura stramonium) or coca leaf extract may be intentionally ingested for its psychoactive hallucinatory effects.2 Although rare in the United States, in certain parts of Asia, persons intent on self-harm may consume toxic plants.1
When ingested, what plants cause bradycardia and hypotension, and why do these effects occur?
The two broad classes of plant-derived toxins that can cause these findings are cardioactive steroids and sodium channel active agents.
Cardioactive Steroids
There are numerous botanical sources of cardioactive steroids (sometimes called cardiac glycosides) such as Digitalis lanata, from which digoxin is derived; and Digitalis purpurea, the source of digitoxin. Poisoning by Digitalis spp, squill, lily of the valley, oleander, yellow oleander, and Cerbera manghas are clinically similar. Cardioactive steroids act pharmacologically to block the sodium-potassium ATPase pump on the myocardial cell membrane. This in turn increases intracellular sodium, which subsequently inhibits the exchange of extracellular sodium for intracellular calcium, leading to inotropy. Clinical manifestations of toxicity include nausea, vomiting, hyperkalemia, bradycardia, cardiac dysrhythmias, and occasionally hypotension—some of which can be life-threatening.
Sodium Channel Active Agents
Several plant toxins affect the flow of sodium by blocking or activating the sodium channel. Both effects alter the rate and strength of cardiac contraction, causing cardiac dysrhythmias.
Aconite is often used in traditional Chinese medicine. In North America, it is mainly derived from Aconitinum napellus, commonly called monkshood, helmet flower, or wolfsbane. It effectively holds open the voltage-dependent sodium channel, increasing cellular excitability. By prolonging the sodium current influx, neuronal and cardiac repolarization eventually slow due to sodium overload, leading to bradycardia and hypotension, as well as neurological effects. Its cardiotoxicity resembles that caused by cardiac glycosides, though a history of paresthesias or muscle weakness may help to differentiate the two toxins.
Veratrum spp include false hellebore, Indian poke, and California hellebore. These plants are occasionally mistaken for leeks (ramps) and can cause vomiting, bradycardia, and hypotension by a mechanism of action similar to aconitine.
Grayanotoxins, a group of diterpenoid toxins found in death camas, azalea, Rhododendron spp, and mountain laurel, can become concentrated in honey made from these plants. Depending on the specific toxin, they variably open or close the sodium channel. In addition to causing bradycardia and hypotension, patients may exhibit mental status changes (“mad honey” poisoning) and seizures.2
Case Continuation
After rapid infusion of 1-liter of normal saline, the patient’s BP was 80/63 mm Hg and HR was 52 beats/minute. His wife arrived to the ED 30-minutes later with a plastic bag containing the red berries the patient had ingested. The emergency physician identified them as Taxus baccata, or more commonly, yew berries. The patient stated that he ingested both the red fleshy aril and chewed the hard central seed.
How is cardiotoxicity from yew berries treated?
Within hours of ingestion, toxicity progresses from nausea, abdominal pain, paresthesias, and ataxia, to bradycardia, cardiac conduction delays, wide-complex ventricular dysrhythmias and mental status changes.3 Although toxicity of Taxus has been known since antiquity, no antidote exists. Ventricular dysrhythmias causing hemodynamic instability should be electrically cardioverted, although there is no evidence to support the safety or efficacy of such therapy. Since the serum, and therefore cardiac concentration of taxine will be identical after cardioversion to its value prior, recurrent dysrhythmias are common.1 Sodium bicarbonate has been inconsistently effective in the treatment of wide-complex tachydysrhythmias,4 but its use seems counterintuitive for most cases. There may be merit to raising the sodium gradient on an already sodium overloaded myocyte, but short-term gain may lead to unintended consequences. Success with antidysrhythmics has been limited: although amiodarone is often used to treat wide-complex tachydysrhythmias, its efficacy in Taxus toxicity has been conflicting.4-6
There have been a few reported cases of yew alkaloid crossreactivity with digoxin assays, suggesting that digoxin-specific antibody fragments may bind taxine.7 There is no evidence, however, that cardioactive steroids are present in yew, and empiric use of antidigoxin Fab-fragments cannot be recommended. A single case report demonstrated that hemodialysis was ineffective in the removal of taxines, likely due to the toxin’s large volume of distribution.8 As a last resort, extracorporeal life support with membrane oxygenation is described favorably in two cases of yew berry poisoning refractory to conventional therapy.9,10
Case Conclusion
The patient’s ECGs showed a morphologically abnormal rhythm, possibly with a Brugada pattern, which are representative of the dysrhythmias caused by taxine’s inhibitory effects on the sodium and calcium channels. Despite an attempt at electrical cardioversion, the dysrhythmia persisted. He was given intravenous boluses of fluids and started on an amiodarone infusion. The patient’s BP gradually improved over the following 2 hours, and the dysrhythmia resolved with hemodynamic improvement. The amiodarone infusion was then discontinued, and he was admitted to the hospital for further testing. Echocardiography, electrophysiology studies, and cardiac catheterization were all normal. The absence of structural, dysrhythmogenic, and ischemic abnormalities supported the toxic etiology of his hemodynamic aberrations. He was discharged from the hospital 3 days later without report of sequelae.
Dr Nguyen is a medical toxicology fellow in the department of emergency medicine at New York University Langone Medical Center. Dr Nelson, editor of “Case Studies in Toxicology,” is a professor in the department of emergency medicine and director of the medical toxicology fellowship program at the New York University School of Medicine and the New York City Poison Control Center. He is also associate editor, toxicology, of the EMERGENCY MEDICINE editorial board.
- Bruneton J. Toxic Plants; Dangerous to Humans and Animals. Paris, France: Lavoisier Publishing; 1999:4-752.
- Palmer ME, Betz JM. Plants. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE. In: Goldfrank’s Toxicologic Emergencies. 9th ed. New York, NY: McGraw Hill; 2010:1537-1560.
- Nelson LS, Shih RD, Balick MJ. Handbook of Poisonous and Injurious Plants. 2nd ed. New York, NY: Springer/New York Botanical Garden; 2007:288-290.
- Pierog J, Kane B, Kane K, Donovan JW. Management of isolated yew berry toxicity with sodium bicarbonate: a case report in treatment efficacy. J Med Toxicol. 2009;5(2):84-89.
- Jones R, Jones J, Causer J, Ewins D, Goenka N, Joseph F. Yew tree poisoning: a near-fatal lesson from history. Clin Med. 2011;11(2):173-175.
- Willaert W, Claessens P, Vankelecom B, Vanderheyden M. Intoxication with Taxus baccata: cardiac arrhythmias following yew leaves ingestion. Pacing Clin Electrophysiol. 2002;25(4 Pt 1):511,512.
- Cummins RO, Haulman J, Quan L, Graves JR, Peterson D, Horan S. Near-fatal yew berry intoxication treated with external cardiac pacing and digoxin-specific FAB antibody fragments. Ann Emerg Med. 1990;19(1):38-43
- Dahlqvist M, Venzin R, König S, et al. Haemodialysis in Taxus baccata poisoning: a case report. QJM. 2012;105(4):359-361.
- Panzeri C, Bacis G, Ferri F, et al. Extracorporeal life support in severe Taxus baccata poisoning. Clin Toxicol. 2010;48(5):463-465.
- Soumagne N, Chauvet S, Chatellier D, Robert R, Charrière JM, Menu P. Treatment of yew leaf intoxication with extracorporeal circulation. Am J Emerg Med. 2011;29(3):354.e5-6.
Case
A 50-year-old man ingests two handfuls of small, red berries that he picked from a shrub in front of his apartment building, with the belief that they would have medicinal value. Two hours later, he developed abdominal cramping and vomited multiple times, followed shortly thereafter by profuse diaphoresis, lethargy, and ataxia. His concerned family brought him to the ED where his vital signs on presentation were: blood pressure (BP), 78/43 mm Hg; heart rate (HR), 50 beats/minute; respiratory rate (RR), 12 breaths/minute; temperature (T), 97.8°F. With the exception of bradycardia, the patient’s cardiac, pulmonary, and abdominal examinations were normal. His skin was diaphoretic, and he had no focal motor or sensory deficits or tremor. Initial laboratory values were: hemoglobin, 12.6 g/dL; sodium, 137 mEq/L; potassium, 4.6 mEq/L; bicarbonate, 20 mEq/L; blood urea nitrogen, 17 mg/dL; creatinine, 2.2 mg/dL; glucose, 288 mg/dL. The patient’s troponin I level was slightly elevated at 0.06 ng/mL; electrocardiogram (ECG) results are shown in Figure 1.
Why do plant poisonings occur?
There is the general belief that what is natural is not only healthful but also safe. This is clearly not true: cyanide, uranium, and king cobras are all natural but hardly safe. While most plants chosen for their purported medicinal properties are generally harmless in most patients when taken in low doses, there are plants that are sufficiently poisonous to be consequential with even relatively small exposures. Some people, often unknowingly vulnerable due to genetic or other causes, are uniquely susceptible to even minute doses.
Humans probably learned about plant toxicity early on—most likely the hard way. To this day, however, the Internet is replete with traditional and avant-garde natural healing remedies involving the use of naturally-derived plant products. These numerous bioactive compounds are often sold in plant form or as extracts, the latter being more concerning given their more concentrated formulation.
Plant misidentification is a common cause of poisoning, whether the intended use is for food or medicine. For example, some mistake “deadly nightshade” (Atropa belladonna) berries, which are deep blue, for blueberries, or pokeweed roots for horseradish roots due to their similar appearances.1
Alternatively, even when a plant is correctly identified, patients may experience adverse effects if they exceed the “therapeutic dose” (eg, dysrhythmia from aconite roots used in traditional Chinese medicine) or if the plant is improperly prepared (eg, hypoglycemia from consuming unripe ackee fruit).2 In addition, a toxic plant such as Jimson weed (Datura stramonium) or coca leaf extract may be intentionally ingested for its psychoactive hallucinatory effects.2 Although rare in the United States, in certain parts of Asia, persons intent on self-harm may consume toxic plants.1
When ingested, what plants cause bradycardia and hypotension, and why do these effects occur?
The two broad classes of plant-derived toxins that can cause these findings are cardioactive steroids and sodium channel active agents.
Cardioactive Steroids
There are numerous botanical sources of cardioactive steroids (sometimes called cardiac glycosides) such as Digitalis lanata, from which digoxin is derived; and Digitalis purpurea, the source of digitoxin. Poisoning by Digitalis spp, squill, lily of the valley, oleander, yellow oleander, and Cerbera manghas are clinically similar. Cardioactive steroids act pharmacologically to block the sodium-potassium ATPase pump on the myocardial cell membrane. This in turn increases intracellular sodium, which subsequently inhibits the exchange of extracellular sodium for intracellular calcium, leading to inotropy. Clinical manifestations of toxicity include nausea, vomiting, hyperkalemia, bradycardia, cardiac dysrhythmias, and occasionally hypotension—some of which can be life-threatening.
Sodium Channel Active Agents
Several plant toxins affect the flow of sodium by blocking or activating the sodium channel. Both effects alter the rate and strength of cardiac contraction, causing cardiac dysrhythmias.
Aconite is often used in traditional Chinese medicine. In North America, it is mainly derived from Aconitinum napellus, commonly called monkshood, helmet flower, or wolfsbane. It effectively holds open the voltage-dependent sodium channel, increasing cellular excitability. By prolonging the sodium current influx, neuronal and cardiac repolarization eventually slow due to sodium overload, leading to bradycardia and hypotension, as well as neurological effects. Its cardiotoxicity resembles that caused by cardiac glycosides, though a history of paresthesias or muscle weakness may help to differentiate the two toxins.
Veratrum spp include false hellebore, Indian poke, and California hellebore. These plants are occasionally mistaken for leeks (ramps) and can cause vomiting, bradycardia, and hypotension by a mechanism of action similar to aconitine.
Grayanotoxins, a group of diterpenoid toxins found in death camas, azalea, Rhododendron spp, and mountain laurel, can become concentrated in honey made from these plants. Depending on the specific toxin, they variably open or close the sodium channel. In addition to causing bradycardia and hypotension, patients may exhibit mental status changes (“mad honey” poisoning) and seizures.2
Case Continuation
After rapid infusion of 1-liter of normal saline, the patient’s BP was 80/63 mm Hg and HR was 52 beats/minute. His wife arrived to the ED 30-minutes later with a plastic bag containing the red berries the patient had ingested. The emergency physician identified them as Taxus baccata, or more commonly, yew berries. The patient stated that he ingested both the red fleshy aril and chewed the hard central seed.
How is cardiotoxicity from yew berries treated?
Within hours of ingestion, toxicity progresses from nausea, abdominal pain, paresthesias, and ataxia, to bradycardia, cardiac conduction delays, wide-complex ventricular dysrhythmias and mental status changes.3 Although toxicity of Taxus has been known since antiquity, no antidote exists. Ventricular dysrhythmias causing hemodynamic instability should be electrically cardioverted, although there is no evidence to support the safety or efficacy of such therapy. Since the serum, and therefore cardiac concentration of taxine will be identical after cardioversion to its value prior, recurrent dysrhythmias are common.1 Sodium bicarbonate has been inconsistently effective in the treatment of wide-complex tachydysrhythmias,4 but its use seems counterintuitive for most cases. There may be merit to raising the sodium gradient on an already sodium overloaded myocyte, but short-term gain may lead to unintended consequences. Success with antidysrhythmics has been limited: although amiodarone is often used to treat wide-complex tachydysrhythmias, its efficacy in Taxus toxicity has been conflicting.4-6
There have been a few reported cases of yew alkaloid crossreactivity with digoxin assays, suggesting that digoxin-specific antibody fragments may bind taxine.7 There is no evidence, however, that cardioactive steroids are present in yew, and empiric use of antidigoxin Fab-fragments cannot be recommended. A single case report demonstrated that hemodialysis was ineffective in the removal of taxines, likely due to the toxin’s large volume of distribution.8 As a last resort, extracorporeal life support with membrane oxygenation is described favorably in two cases of yew berry poisoning refractory to conventional therapy.9,10
Case Conclusion
The patient’s ECGs showed a morphologically abnormal rhythm, possibly with a Brugada pattern, which are representative of the dysrhythmias caused by taxine’s inhibitory effects on the sodium and calcium channels. Despite an attempt at electrical cardioversion, the dysrhythmia persisted. He was given intravenous boluses of fluids and started on an amiodarone infusion. The patient’s BP gradually improved over the following 2 hours, and the dysrhythmia resolved with hemodynamic improvement. The amiodarone infusion was then discontinued, and he was admitted to the hospital for further testing. Echocardiography, electrophysiology studies, and cardiac catheterization were all normal. The absence of structural, dysrhythmogenic, and ischemic abnormalities supported the toxic etiology of his hemodynamic aberrations. He was discharged from the hospital 3 days later without report of sequelae.
Dr Nguyen is a medical toxicology fellow in the department of emergency medicine at New York University Langone Medical Center. Dr Nelson, editor of “Case Studies in Toxicology,” is a professor in the department of emergency medicine and director of the medical toxicology fellowship program at the New York University School of Medicine and the New York City Poison Control Center. He is also associate editor, toxicology, of the EMERGENCY MEDICINE editorial board.
Case
A 50-year-old man ingests two handfuls of small, red berries that he picked from a shrub in front of his apartment building, with the belief that they would have medicinal value. Two hours later, he developed abdominal cramping and vomited multiple times, followed shortly thereafter by profuse diaphoresis, lethargy, and ataxia. His concerned family brought him to the ED where his vital signs on presentation were: blood pressure (BP), 78/43 mm Hg; heart rate (HR), 50 beats/minute; respiratory rate (RR), 12 breaths/minute; temperature (T), 97.8°F. With the exception of bradycardia, the patient’s cardiac, pulmonary, and abdominal examinations were normal. His skin was diaphoretic, and he had no focal motor or sensory deficits or tremor. Initial laboratory values were: hemoglobin, 12.6 g/dL; sodium, 137 mEq/L; potassium, 4.6 mEq/L; bicarbonate, 20 mEq/L; blood urea nitrogen, 17 mg/dL; creatinine, 2.2 mg/dL; glucose, 288 mg/dL. The patient’s troponin I level was slightly elevated at 0.06 ng/mL; electrocardiogram (ECG) results are shown in Figure 1.
Why do plant poisonings occur?
There is the general belief that what is natural is not only healthful but also safe. This is clearly not true: cyanide, uranium, and king cobras are all natural but hardly safe. While most plants chosen for their purported medicinal properties are generally harmless in most patients when taken in low doses, there are plants that are sufficiently poisonous to be consequential with even relatively small exposures. Some people, often unknowingly vulnerable due to genetic or other causes, are uniquely susceptible to even minute doses.
Humans probably learned about plant toxicity early on—most likely the hard way. To this day, however, the Internet is replete with traditional and avant-garde natural healing remedies involving the use of naturally-derived plant products. These numerous bioactive compounds are often sold in plant form or as extracts, the latter being more concerning given their more concentrated formulation.
Plant misidentification is a common cause of poisoning, whether the intended use is for food or medicine. For example, some mistake “deadly nightshade” (Atropa belladonna) berries, which are deep blue, for blueberries, or pokeweed roots for horseradish roots due to their similar appearances.1
Alternatively, even when a plant is correctly identified, patients may experience adverse effects if they exceed the “therapeutic dose” (eg, dysrhythmia from aconite roots used in traditional Chinese medicine) or if the plant is improperly prepared (eg, hypoglycemia from consuming unripe ackee fruit).2 In addition, a toxic plant such as Jimson weed (Datura stramonium) or coca leaf extract may be intentionally ingested for its psychoactive hallucinatory effects.2 Although rare in the United States, in certain parts of Asia, persons intent on self-harm may consume toxic plants.1
When ingested, what plants cause bradycardia and hypotension, and why do these effects occur?
The two broad classes of plant-derived toxins that can cause these findings are cardioactive steroids and sodium channel active agents.
Cardioactive Steroids
There are numerous botanical sources of cardioactive steroids (sometimes called cardiac glycosides) such as Digitalis lanata, from which digoxin is derived; and Digitalis purpurea, the source of digitoxin. Poisoning by Digitalis spp, squill, lily of the valley, oleander, yellow oleander, and Cerbera manghas are clinically similar. Cardioactive steroids act pharmacologically to block the sodium-potassium ATPase pump on the myocardial cell membrane. This in turn increases intracellular sodium, which subsequently inhibits the exchange of extracellular sodium for intracellular calcium, leading to inotropy. Clinical manifestations of toxicity include nausea, vomiting, hyperkalemia, bradycardia, cardiac dysrhythmias, and occasionally hypotension—some of which can be life-threatening.
Sodium Channel Active Agents
Several plant toxins affect the flow of sodium by blocking or activating the sodium channel. Both effects alter the rate and strength of cardiac contraction, causing cardiac dysrhythmias.
Aconite is often used in traditional Chinese medicine. In North America, it is mainly derived from Aconitinum napellus, commonly called monkshood, helmet flower, or wolfsbane. It effectively holds open the voltage-dependent sodium channel, increasing cellular excitability. By prolonging the sodium current influx, neuronal and cardiac repolarization eventually slow due to sodium overload, leading to bradycardia and hypotension, as well as neurological effects. Its cardiotoxicity resembles that caused by cardiac glycosides, though a history of paresthesias or muscle weakness may help to differentiate the two toxins.
Veratrum spp include false hellebore, Indian poke, and California hellebore. These plants are occasionally mistaken for leeks (ramps) and can cause vomiting, bradycardia, and hypotension by a mechanism of action similar to aconitine.
Grayanotoxins, a group of diterpenoid toxins found in death camas, azalea, Rhododendron spp, and mountain laurel, can become concentrated in honey made from these plants. Depending on the specific toxin, they variably open or close the sodium channel. In addition to causing bradycardia and hypotension, patients may exhibit mental status changes (“mad honey” poisoning) and seizures.2
Case Continuation
After rapid infusion of 1-liter of normal saline, the patient’s BP was 80/63 mm Hg and HR was 52 beats/minute. His wife arrived to the ED 30-minutes later with a plastic bag containing the red berries the patient had ingested. The emergency physician identified them as Taxus baccata, or more commonly, yew berries. The patient stated that he ingested both the red fleshy aril and chewed the hard central seed.
How is cardiotoxicity from yew berries treated?
Within hours of ingestion, toxicity progresses from nausea, abdominal pain, paresthesias, and ataxia, to bradycardia, cardiac conduction delays, wide-complex ventricular dysrhythmias and mental status changes.3 Although toxicity of Taxus has been known since antiquity, no antidote exists. Ventricular dysrhythmias causing hemodynamic instability should be electrically cardioverted, although there is no evidence to support the safety or efficacy of such therapy. Since the serum, and therefore cardiac concentration of taxine will be identical after cardioversion to its value prior, recurrent dysrhythmias are common.1 Sodium bicarbonate has been inconsistently effective in the treatment of wide-complex tachydysrhythmias,4 but its use seems counterintuitive for most cases. There may be merit to raising the sodium gradient on an already sodium overloaded myocyte, but short-term gain may lead to unintended consequences. Success with antidysrhythmics has been limited: although amiodarone is often used to treat wide-complex tachydysrhythmias, its efficacy in Taxus toxicity has been conflicting.4-6
There have been a few reported cases of yew alkaloid crossreactivity with digoxin assays, suggesting that digoxin-specific antibody fragments may bind taxine.7 There is no evidence, however, that cardioactive steroids are present in yew, and empiric use of antidigoxin Fab-fragments cannot be recommended. A single case report demonstrated that hemodialysis was ineffective in the removal of taxines, likely due to the toxin’s large volume of distribution.8 As a last resort, extracorporeal life support with membrane oxygenation is described favorably in two cases of yew berry poisoning refractory to conventional therapy.9,10
Case Conclusion
The patient’s ECGs showed a morphologically abnormal rhythm, possibly with a Brugada pattern, which are representative of the dysrhythmias caused by taxine’s inhibitory effects on the sodium and calcium channels. Despite an attempt at electrical cardioversion, the dysrhythmia persisted. He was given intravenous boluses of fluids and started on an amiodarone infusion. The patient’s BP gradually improved over the following 2 hours, and the dysrhythmia resolved with hemodynamic improvement. The amiodarone infusion was then discontinued, and he was admitted to the hospital for further testing. Echocardiography, electrophysiology studies, and cardiac catheterization were all normal. The absence of structural, dysrhythmogenic, and ischemic abnormalities supported the toxic etiology of his hemodynamic aberrations. He was discharged from the hospital 3 days later without report of sequelae.
Dr Nguyen is a medical toxicology fellow in the department of emergency medicine at New York University Langone Medical Center. Dr Nelson, editor of “Case Studies in Toxicology,” is a professor in the department of emergency medicine and director of the medical toxicology fellowship program at the New York University School of Medicine and the New York City Poison Control Center. He is also associate editor, toxicology, of the EMERGENCY MEDICINE editorial board.
- Bruneton J. Toxic Plants; Dangerous to Humans and Animals. Paris, France: Lavoisier Publishing; 1999:4-752.
- Palmer ME, Betz JM. Plants. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE. In: Goldfrank’s Toxicologic Emergencies. 9th ed. New York, NY: McGraw Hill; 2010:1537-1560.
- Nelson LS, Shih RD, Balick MJ. Handbook of Poisonous and Injurious Plants. 2nd ed. New York, NY: Springer/New York Botanical Garden; 2007:288-290.
- Pierog J, Kane B, Kane K, Donovan JW. Management of isolated yew berry toxicity with sodium bicarbonate: a case report in treatment efficacy. J Med Toxicol. 2009;5(2):84-89.
- Jones R, Jones J, Causer J, Ewins D, Goenka N, Joseph F. Yew tree poisoning: a near-fatal lesson from history. Clin Med. 2011;11(2):173-175.
- Willaert W, Claessens P, Vankelecom B, Vanderheyden M. Intoxication with Taxus baccata: cardiac arrhythmias following yew leaves ingestion. Pacing Clin Electrophysiol. 2002;25(4 Pt 1):511,512.
- Cummins RO, Haulman J, Quan L, Graves JR, Peterson D, Horan S. Near-fatal yew berry intoxication treated with external cardiac pacing and digoxin-specific FAB antibody fragments. Ann Emerg Med. 1990;19(1):38-43
- Dahlqvist M, Venzin R, König S, et al. Haemodialysis in Taxus baccata poisoning: a case report. QJM. 2012;105(4):359-361.
- Panzeri C, Bacis G, Ferri F, et al. Extracorporeal life support in severe Taxus baccata poisoning. Clin Toxicol. 2010;48(5):463-465.
- Soumagne N, Chauvet S, Chatellier D, Robert R, Charrière JM, Menu P. Treatment of yew leaf intoxication with extracorporeal circulation. Am J Emerg Med. 2011;29(3):354.e5-6.
- Bruneton J. Toxic Plants; Dangerous to Humans and Animals. Paris, France: Lavoisier Publishing; 1999:4-752.
- Palmer ME, Betz JM. Plants. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE. In: Goldfrank’s Toxicologic Emergencies. 9th ed. New York, NY: McGraw Hill; 2010:1537-1560.
- Nelson LS, Shih RD, Balick MJ. Handbook of Poisonous and Injurious Plants. 2nd ed. New York, NY: Springer/New York Botanical Garden; 2007:288-290.
- Pierog J, Kane B, Kane K, Donovan JW. Management of isolated yew berry toxicity with sodium bicarbonate: a case report in treatment efficacy. J Med Toxicol. 2009;5(2):84-89.
- Jones R, Jones J, Causer J, Ewins D, Goenka N, Joseph F. Yew tree poisoning: a near-fatal lesson from history. Clin Med. 2011;11(2):173-175.
- Willaert W, Claessens P, Vankelecom B, Vanderheyden M. Intoxication with Taxus baccata: cardiac arrhythmias following yew leaves ingestion. Pacing Clin Electrophysiol. 2002;25(4 Pt 1):511,512.
- Cummins RO, Haulman J, Quan L, Graves JR, Peterson D, Horan S. Near-fatal yew berry intoxication treated with external cardiac pacing and digoxin-specific FAB antibody fragments. Ann Emerg Med. 1990;19(1):38-43
- Dahlqvist M, Venzin R, König S, et al. Haemodialysis in Taxus baccata poisoning: a case report. QJM. 2012;105(4):359-361.
- Panzeri C, Bacis G, Ferri F, et al. Extracorporeal life support in severe Taxus baccata poisoning. Clin Toxicol. 2010;48(5):463-465.
- Soumagne N, Chauvet S, Chatellier D, Robert R, Charrière JM, Menu P. Treatment of yew leaf intoxication with extracorporeal circulation. Am J Emerg Med. 2011;29(3):354.e5-6.
Case Report: An Unusual Case of Arrhythmia
Case
A 3-year-old girl presented to the ED with a 1-week history of cough and new-onset abdominal pain. She was accompanied by her grandfather, who stated that the child had been dropped-off at his house around 5:00 pm the previous day. He noted that after putting his granddaughter to bed, she awoke around 4:30 am complaining of a stomachache. After rocking her, he said she went back to sleep but did not wake up again until 1:00 pm that afternoon. Over the first few hours of awakening, she became less active and had three episodes of posttussive emesis. The grandfather denied the child had any recent nasal congestion, fever, nausea, vomiting, or diarrhea. When questioned about possible toxic ingestion, he said there were no medications in the house and that he did not witness any substance ingestion or trauma.
At presentation, the patient’s vital signs were: blood pressure (BP) 86/49 mm Hg; heart rate (HR), 178 beats/minute and regular; respiratory rate (RR), 26 breaths/minute; temporal artery temperature, 104.7°F. Oxygen saturation was 99% on room air. On physical examination, she was normocephalic; there was no scleral icterus; and the throat and bilateral tympanic membranes were normal. Her extremities were warm and well perfused, with normal capillary refill. Patient’s lungs were clear, and heart sounds were normal with no detection of a murmur. The abdomen was soft and nontender; there was no evidence of organomegaly.
Laboratory evaluation included assessment of sodium, chloride, carbon dioxide, calcium, magnesium, amylase, lipase, and creatine levels; liver function test; complete blood count; and red-cell indices. All of the laboratory values were within normal limits, and urinalysis was negative for infection. Blood and urine cultures were also taken. A chest X-ray showed no acute intrathoracic process (Figure 1).
During treatment, the patient became increasingly fussy with new-onset abdominal distension. Repeat physical examination revealed hepatomegaly. A bedside echocardiogram showed hyperdynamic heart with fractional shortening* (FS) of 20% and ejection fraction (EF) of 43%, but no structural abnormalities. An electrocardiogram (ECG) was then ordered, which revealed narrow complex tachycardia with inverted P-waves in inferior leads.
Discussion
Normal cardiac conduction involves an originating impulse from a sinus node followed by atrial muscle activation reaching the atrioventricular (AV) node. There is a necessary delay at the AV node, which is required for ventricular filling and activation of ventricles through the His-Purkinje fiber system and the bundle branches. An abnormality or interruption of this pathway results in an arrhythmia such as supraventricular tachycardia (SVT).
Supraventricular Tachycardia
Supraventricular tachycardia is the most common symptomatic abnormality in the pediatric population.1 Among the various forms of SVT, AV reentrant tachycardia (AVRT) and AV node reentrant tachycardia (AVNRT) account for most case presentations.2 Supraventricular tachycardia may be classified by duration of RP interval compared to PR interval on ECG. Short RP interval SVT includes AVNRT and AVRT through a rapidly conducting accessory path. Long RP interval SVT includes atypical AVNRT, atrial tachycardia, and PJRT.
Persistent Junctional Reentrant Tachycardia
Persistent junctional reentrant tachycardia is a rare form of long RP tachycardia, accounting for approximately 1% of SVT in a study review of 21 patients.3 As with the patient in this case, PJRT usually presents in early childhood.3 In a recent review of 194 patients with PJRT, 57% were infants.4 The condition involves an accessory pathway most commonly located in the posterior-superior septal region; conduction involves a retrograde impulse through the decremental accessory pathway.5 On ECG, findings include a negative P wave in inferior leads, a long RP interval, and a 1:1 AV conduction.6
A long-term multicenter follow-up study of 32 patients showed that rates of tachycardia vary among patients, from 100 to 250 beats/minute.7 Tachycardia-induced cardiomyopathy (TIC), which is secondary to the incessant nature of tachycardia, may be present in up to 30% to 50% of patients.3,8 In a recent multicenter study, PJRT was responsible for 23% of cases of TIC.9 Although the exact mechanism of this property is unknown, decremental conduction and unidirectional block of the accessory pathway appear to be contributing factors.6
Treatment
Adenosine is the initial drug of choice for narrow complex tachycardia with stable hemodynamic status and an available intravascular access.10 In a study evaluating the effectiveness of adenosine for managing SVT in the pediatric ED setting, it was more than 70% effective in cardioverting patients presumed to have SVT.11 However, in PJRT, owing to the incessant pattern, adenosine may either terminate the tachycardia (causing asystole) or, as seen in this patient, convert tachycardia to sinus rhythm for only a few seconds.12 Reinitiation of tachycardia in sinus beat without the need for a premature complex contributes to its incessant nature.13
In a multicenter study looking at clinical profile and outcome for PJRT, Vaksmann et al8 found a greater than 80% success rate in controlling the dysrhythmia with amiodarone and verapamil. For long-term management of tachyarrhythmia, medical therapy has been recommended in early childhood compared to older children in whom catheter ablation is an effective approach.7 Spontaneous resolution of PJRT has been documented but is rare.14
Conclusion
Pediatric cardiac emergencies require very specific treatment. As such, it is important that the emergency physician distinguish the different the types of tachyarrhythmias—especially in cases that do not respond to treatment with adenosine. In the pediatric patient, PJRT is a potentially life-threatening arrhythmia that requires a high index of suspicion. Clues to diagnosis include negative P waves in inferior leads, long RP interval, and 1:1 atrioventricular conduction.
Dr Fichadia is a fellow, pediatric emergency medicine, Wayne State University, Children’s Hospital of Michigan. Dr Perez is a clinical instructor, pediatric emergency medicine, Wayne State University, Children’s Hospital of Michigan.
- Doniger SJ, Sharieff GQ. Pediatric dysrhythmias. Pediatr Clin North Am. 2006; 53(1):85-105, vi.
- Ko JK, Deal BJ, Strasburger JF, Benson DW Jr. Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol. 1992;69(12):1028-1032.
- Dorostkar PC, Silka MJ, Morady F, Dick M 2nd. Clinical course of persistent junctional reciprocating tachycardia. J Am Coll Cardiol. 1999;33(2):366-375.
- Kang KT, Potts JE, Radbill AE, et al. Permanent junctional reciprocating tachycardia in children: A multi-center experience: Permanent junctional reciprocating tachycardia [published online ahead of print April 24, 2014]. Heart Rhythm. doi:10.1016/j.hrthm.2014.04.033.
- Fox DJ, Tischenko A, Krahn AD, et al. Supraventricular tachycardia: diagnosis and management. Mayo Clin Proc. 2008;83(12):1400-1411.
- O’Neill BJ, Klein GJ, Guiraudon GM, et al. Results of operative therapy in the permanent form of junctional reciprocating tachycardia. Am J Cardiol. 1989;63(15):1074-1079.
- Lindinger A, Heisel A, von Bernuth G, et al., Permanent junctional re-entry tachycardia. A multicentre long-term follow-up study in infants, children and young adults. Eur Heart J. 1998;19(6):936-942.
- Vaksmann G, D’Hoinne C, Lucet V. Permanent junctional reciprocating tachycardia in children: a multicentre study on clinical profile and outcome. Heart. 2006;92(1):101-104.
- Moore JP, Patel PA, Shannon KM, et al. Predictors of Myocardial Recovery in Pediatric Tachycardia-Induced Cardiomyopathy [published online ahead of print April 18, 2014]. Heart Rhythm. doi:10.1016/j.hrthm.2014.04.023.
- Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18 Suppl 3):S876-S908.
- Losek JD, Endom E, Dietrich A, Stewart G, Zempsky W, Smith K. Adenosine and pediatric supraventricular tachycardia in the emergency department: multicenter study and review. Ann Emerg Med. 1999;33(2):185-191.
- Waisman Y, Berman S, Fogelman R, Zeevi B, Mimouni M. Failure of adenosine to convert subtype of supraventricular tachycardia. Israeli J Emerg Med. 2003;3(2):4-7.
- Ho, Reginald T. Unusual manifestations of accessory pathways. In: Electrophysiology of Arrhythmias: Practical Images for Diagnosis and Ablation. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:167.
- Brugada J, Blom N, Sarquella-Brugada G, et al; European Heart Rhythm Association; Association for European Paediatric and Congenital Cardiology. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15(9):1337-1382.
* Fractional shortening is the percent of shortening of left ventricular diameter between end-diastole to end-systole with a normal range of 28% to 44%. In the presence of myocardial depression, FS values are reduced.
Case
A 3-year-old girl presented to the ED with a 1-week history of cough and new-onset abdominal pain. She was accompanied by her grandfather, who stated that the child had been dropped-off at his house around 5:00 pm the previous day. He noted that after putting his granddaughter to bed, she awoke around 4:30 am complaining of a stomachache. After rocking her, he said she went back to sleep but did not wake up again until 1:00 pm that afternoon. Over the first few hours of awakening, she became less active and had three episodes of posttussive emesis. The grandfather denied the child had any recent nasal congestion, fever, nausea, vomiting, or diarrhea. When questioned about possible toxic ingestion, he said there were no medications in the house and that he did not witness any substance ingestion or trauma.
At presentation, the patient’s vital signs were: blood pressure (BP) 86/49 mm Hg; heart rate (HR), 178 beats/minute and regular; respiratory rate (RR), 26 breaths/minute; temporal artery temperature, 104.7°F. Oxygen saturation was 99% on room air. On physical examination, she was normocephalic; there was no scleral icterus; and the throat and bilateral tympanic membranes were normal. Her extremities were warm and well perfused, with normal capillary refill. Patient’s lungs were clear, and heart sounds were normal with no detection of a murmur. The abdomen was soft and nontender; there was no evidence of organomegaly.
Laboratory evaluation included assessment of sodium, chloride, carbon dioxide, calcium, magnesium, amylase, lipase, and creatine levels; liver function test; complete blood count; and red-cell indices. All of the laboratory values were within normal limits, and urinalysis was negative for infection. Blood and urine cultures were also taken. A chest X-ray showed no acute intrathoracic process (Figure 1).
During treatment, the patient became increasingly fussy with new-onset abdominal distension. Repeat physical examination revealed hepatomegaly. A bedside echocardiogram showed hyperdynamic heart with fractional shortening* (FS) of 20% and ejection fraction (EF) of 43%, but no structural abnormalities. An electrocardiogram (ECG) was then ordered, which revealed narrow complex tachycardia with inverted P-waves in inferior leads.
Discussion
Normal cardiac conduction involves an originating impulse from a sinus node followed by atrial muscle activation reaching the atrioventricular (AV) node. There is a necessary delay at the AV node, which is required for ventricular filling and activation of ventricles through the His-Purkinje fiber system and the bundle branches. An abnormality or interruption of this pathway results in an arrhythmia such as supraventricular tachycardia (SVT).
Supraventricular Tachycardia
Supraventricular tachycardia is the most common symptomatic abnormality in the pediatric population.1 Among the various forms of SVT, AV reentrant tachycardia (AVRT) and AV node reentrant tachycardia (AVNRT) account for most case presentations.2 Supraventricular tachycardia may be classified by duration of RP interval compared to PR interval on ECG. Short RP interval SVT includes AVNRT and AVRT through a rapidly conducting accessory path. Long RP interval SVT includes atypical AVNRT, atrial tachycardia, and PJRT.
Persistent Junctional Reentrant Tachycardia
Persistent junctional reentrant tachycardia is a rare form of long RP tachycardia, accounting for approximately 1% of SVT in a study review of 21 patients.3 As with the patient in this case, PJRT usually presents in early childhood.3 In a recent review of 194 patients with PJRT, 57% were infants.4 The condition involves an accessory pathway most commonly located in the posterior-superior septal region; conduction involves a retrograde impulse through the decremental accessory pathway.5 On ECG, findings include a negative P wave in inferior leads, a long RP interval, and a 1:1 AV conduction.6
A long-term multicenter follow-up study of 32 patients showed that rates of tachycardia vary among patients, from 100 to 250 beats/minute.7 Tachycardia-induced cardiomyopathy (TIC), which is secondary to the incessant nature of tachycardia, may be present in up to 30% to 50% of patients.3,8 In a recent multicenter study, PJRT was responsible for 23% of cases of TIC.9 Although the exact mechanism of this property is unknown, decremental conduction and unidirectional block of the accessory pathway appear to be contributing factors.6
Treatment
Adenosine is the initial drug of choice for narrow complex tachycardia with stable hemodynamic status and an available intravascular access.10 In a study evaluating the effectiveness of adenosine for managing SVT in the pediatric ED setting, it was more than 70% effective in cardioverting patients presumed to have SVT.11 However, in PJRT, owing to the incessant pattern, adenosine may either terminate the tachycardia (causing asystole) or, as seen in this patient, convert tachycardia to sinus rhythm for only a few seconds.12 Reinitiation of tachycardia in sinus beat without the need for a premature complex contributes to its incessant nature.13
In a multicenter study looking at clinical profile and outcome for PJRT, Vaksmann et al8 found a greater than 80% success rate in controlling the dysrhythmia with amiodarone and verapamil. For long-term management of tachyarrhythmia, medical therapy has been recommended in early childhood compared to older children in whom catheter ablation is an effective approach.7 Spontaneous resolution of PJRT has been documented but is rare.14
Conclusion
Pediatric cardiac emergencies require very specific treatment. As such, it is important that the emergency physician distinguish the different the types of tachyarrhythmias—especially in cases that do not respond to treatment with adenosine. In the pediatric patient, PJRT is a potentially life-threatening arrhythmia that requires a high index of suspicion. Clues to diagnosis include negative P waves in inferior leads, long RP interval, and 1:1 atrioventricular conduction.
Dr Fichadia is a fellow, pediatric emergency medicine, Wayne State University, Children’s Hospital of Michigan. Dr Perez is a clinical instructor, pediatric emergency medicine, Wayne State University, Children’s Hospital of Michigan.
Case
A 3-year-old girl presented to the ED with a 1-week history of cough and new-onset abdominal pain. She was accompanied by her grandfather, who stated that the child had been dropped-off at his house around 5:00 pm the previous day. He noted that after putting his granddaughter to bed, she awoke around 4:30 am complaining of a stomachache. After rocking her, he said she went back to sleep but did not wake up again until 1:00 pm that afternoon. Over the first few hours of awakening, she became less active and had three episodes of posttussive emesis. The grandfather denied the child had any recent nasal congestion, fever, nausea, vomiting, or diarrhea. When questioned about possible toxic ingestion, he said there were no medications in the house and that he did not witness any substance ingestion or trauma.
At presentation, the patient’s vital signs were: blood pressure (BP) 86/49 mm Hg; heart rate (HR), 178 beats/minute and regular; respiratory rate (RR), 26 breaths/minute; temporal artery temperature, 104.7°F. Oxygen saturation was 99% on room air. On physical examination, she was normocephalic; there was no scleral icterus; and the throat and bilateral tympanic membranes were normal. Her extremities were warm and well perfused, with normal capillary refill. Patient’s lungs were clear, and heart sounds were normal with no detection of a murmur. The abdomen was soft and nontender; there was no evidence of organomegaly.
Laboratory evaluation included assessment of sodium, chloride, carbon dioxide, calcium, magnesium, amylase, lipase, and creatine levels; liver function test; complete blood count; and red-cell indices. All of the laboratory values were within normal limits, and urinalysis was negative for infection. Blood and urine cultures were also taken. A chest X-ray showed no acute intrathoracic process (Figure 1).
During treatment, the patient became increasingly fussy with new-onset abdominal distension. Repeat physical examination revealed hepatomegaly. A bedside echocardiogram showed hyperdynamic heart with fractional shortening* (FS) of 20% and ejection fraction (EF) of 43%, but no structural abnormalities. An electrocardiogram (ECG) was then ordered, which revealed narrow complex tachycardia with inverted P-waves in inferior leads.
Discussion
Normal cardiac conduction involves an originating impulse from a sinus node followed by atrial muscle activation reaching the atrioventricular (AV) node. There is a necessary delay at the AV node, which is required for ventricular filling and activation of ventricles through the His-Purkinje fiber system and the bundle branches. An abnormality or interruption of this pathway results in an arrhythmia such as supraventricular tachycardia (SVT).
Supraventricular Tachycardia
Supraventricular tachycardia is the most common symptomatic abnormality in the pediatric population.1 Among the various forms of SVT, AV reentrant tachycardia (AVRT) and AV node reentrant tachycardia (AVNRT) account for most case presentations.2 Supraventricular tachycardia may be classified by duration of RP interval compared to PR interval on ECG. Short RP interval SVT includes AVNRT and AVRT through a rapidly conducting accessory path. Long RP interval SVT includes atypical AVNRT, atrial tachycardia, and PJRT.
Persistent Junctional Reentrant Tachycardia
Persistent junctional reentrant tachycardia is a rare form of long RP tachycardia, accounting for approximately 1% of SVT in a study review of 21 patients.3 As with the patient in this case, PJRT usually presents in early childhood.3 In a recent review of 194 patients with PJRT, 57% were infants.4 The condition involves an accessory pathway most commonly located in the posterior-superior septal region; conduction involves a retrograde impulse through the decremental accessory pathway.5 On ECG, findings include a negative P wave in inferior leads, a long RP interval, and a 1:1 AV conduction.6
A long-term multicenter follow-up study of 32 patients showed that rates of tachycardia vary among patients, from 100 to 250 beats/minute.7 Tachycardia-induced cardiomyopathy (TIC), which is secondary to the incessant nature of tachycardia, may be present in up to 30% to 50% of patients.3,8 In a recent multicenter study, PJRT was responsible for 23% of cases of TIC.9 Although the exact mechanism of this property is unknown, decremental conduction and unidirectional block of the accessory pathway appear to be contributing factors.6
Treatment
Adenosine is the initial drug of choice for narrow complex tachycardia with stable hemodynamic status and an available intravascular access.10 In a study evaluating the effectiveness of adenosine for managing SVT in the pediatric ED setting, it was more than 70% effective in cardioverting patients presumed to have SVT.11 However, in PJRT, owing to the incessant pattern, adenosine may either terminate the tachycardia (causing asystole) or, as seen in this patient, convert tachycardia to sinus rhythm for only a few seconds.12 Reinitiation of tachycardia in sinus beat without the need for a premature complex contributes to its incessant nature.13
In a multicenter study looking at clinical profile and outcome for PJRT, Vaksmann et al8 found a greater than 80% success rate in controlling the dysrhythmia with amiodarone and verapamil. For long-term management of tachyarrhythmia, medical therapy has been recommended in early childhood compared to older children in whom catheter ablation is an effective approach.7 Spontaneous resolution of PJRT has been documented but is rare.14
Conclusion
Pediatric cardiac emergencies require very specific treatment. As such, it is important that the emergency physician distinguish the different the types of tachyarrhythmias—especially in cases that do not respond to treatment with adenosine. In the pediatric patient, PJRT is a potentially life-threatening arrhythmia that requires a high index of suspicion. Clues to diagnosis include negative P waves in inferior leads, long RP interval, and 1:1 atrioventricular conduction.
Dr Fichadia is a fellow, pediatric emergency medicine, Wayne State University, Children’s Hospital of Michigan. Dr Perez is a clinical instructor, pediatric emergency medicine, Wayne State University, Children’s Hospital of Michigan.
- Doniger SJ, Sharieff GQ. Pediatric dysrhythmias. Pediatr Clin North Am. 2006; 53(1):85-105, vi.
- Ko JK, Deal BJ, Strasburger JF, Benson DW Jr. Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol. 1992;69(12):1028-1032.
- Dorostkar PC, Silka MJ, Morady F, Dick M 2nd. Clinical course of persistent junctional reciprocating tachycardia. J Am Coll Cardiol. 1999;33(2):366-375.
- Kang KT, Potts JE, Radbill AE, et al. Permanent junctional reciprocating tachycardia in children: A multi-center experience: Permanent junctional reciprocating tachycardia [published online ahead of print April 24, 2014]. Heart Rhythm. doi:10.1016/j.hrthm.2014.04.033.
- Fox DJ, Tischenko A, Krahn AD, et al. Supraventricular tachycardia: diagnosis and management. Mayo Clin Proc. 2008;83(12):1400-1411.
- O’Neill BJ, Klein GJ, Guiraudon GM, et al. Results of operative therapy in the permanent form of junctional reciprocating tachycardia. Am J Cardiol. 1989;63(15):1074-1079.
- Lindinger A, Heisel A, von Bernuth G, et al., Permanent junctional re-entry tachycardia. A multicentre long-term follow-up study in infants, children and young adults. Eur Heart J. 1998;19(6):936-942.
- Vaksmann G, D’Hoinne C, Lucet V. Permanent junctional reciprocating tachycardia in children: a multicentre study on clinical profile and outcome. Heart. 2006;92(1):101-104.
- Moore JP, Patel PA, Shannon KM, et al. Predictors of Myocardial Recovery in Pediatric Tachycardia-Induced Cardiomyopathy [published online ahead of print April 18, 2014]. Heart Rhythm. doi:10.1016/j.hrthm.2014.04.023.
- Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18 Suppl 3):S876-S908.
- Losek JD, Endom E, Dietrich A, Stewart G, Zempsky W, Smith K. Adenosine and pediatric supraventricular tachycardia in the emergency department: multicenter study and review. Ann Emerg Med. 1999;33(2):185-191.
- Waisman Y, Berman S, Fogelman R, Zeevi B, Mimouni M. Failure of adenosine to convert subtype of supraventricular tachycardia. Israeli J Emerg Med. 2003;3(2):4-7.
- Ho, Reginald T. Unusual manifestations of accessory pathways. In: Electrophysiology of Arrhythmias: Practical Images for Diagnosis and Ablation. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:167.
- Brugada J, Blom N, Sarquella-Brugada G, et al; European Heart Rhythm Association; Association for European Paediatric and Congenital Cardiology. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15(9):1337-1382.
* Fractional shortening is the percent of shortening of left ventricular diameter between end-diastole to end-systole with a normal range of 28% to 44%. In the presence of myocardial depression, FS values are reduced.
- Doniger SJ, Sharieff GQ. Pediatric dysrhythmias. Pediatr Clin North Am. 2006; 53(1):85-105, vi.
- Ko JK, Deal BJ, Strasburger JF, Benson DW Jr. Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol. 1992;69(12):1028-1032.
- Dorostkar PC, Silka MJ, Morady F, Dick M 2nd. Clinical course of persistent junctional reciprocating tachycardia. J Am Coll Cardiol. 1999;33(2):366-375.
- Kang KT, Potts JE, Radbill AE, et al. Permanent junctional reciprocating tachycardia in children: A multi-center experience: Permanent junctional reciprocating tachycardia [published online ahead of print April 24, 2014]. Heart Rhythm. doi:10.1016/j.hrthm.2014.04.033.
- Fox DJ, Tischenko A, Krahn AD, et al. Supraventricular tachycardia: diagnosis and management. Mayo Clin Proc. 2008;83(12):1400-1411.
- O’Neill BJ, Klein GJ, Guiraudon GM, et al. Results of operative therapy in the permanent form of junctional reciprocating tachycardia. Am J Cardiol. 1989;63(15):1074-1079.
- Lindinger A, Heisel A, von Bernuth G, et al., Permanent junctional re-entry tachycardia. A multicentre long-term follow-up study in infants, children and young adults. Eur Heart J. 1998;19(6):936-942.
- Vaksmann G, D’Hoinne C, Lucet V. Permanent junctional reciprocating tachycardia in children: a multicentre study on clinical profile and outcome. Heart. 2006;92(1):101-104.
- Moore JP, Patel PA, Shannon KM, et al. Predictors of Myocardial Recovery in Pediatric Tachycardia-Induced Cardiomyopathy [published online ahead of print April 18, 2014]. Heart Rhythm. doi:10.1016/j.hrthm.2014.04.023.
- Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18 Suppl 3):S876-S908.
- Losek JD, Endom E, Dietrich A, Stewart G, Zempsky W, Smith K. Adenosine and pediatric supraventricular tachycardia in the emergency department: multicenter study and review. Ann Emerg Med. 1999;33(2):185-191.
- Waisman Y, Berman S, Fogelman R, Zeevi B, Mimouni M. Failure of adenosine to convert subtype of supraventricular tachycardia. Israeli J Emerg Med. 2003;3(2):4-7.
- Ho, Reginald T. Unusual manifestations of accessory pathways. In: Electrophysiology of Arrhythmias: Practical Images for Diagnosis and Ablation. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:167.
- Brugada J, Blom N, Sarquella-Brugada G, et al; European Heart Rhythm Association; Association for European Paediatric and Congenital Cardiology. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15(9):1337-1382.
* Fractional shortening is the percent of shortening of left ventricular diameter between end-diastole to end-systole with a normal range of 28% to 44%. In the presence of myocardial depression, FS values are reduced.